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Introduction
Skin cancer (SC) is the most frequent diagnosed cancer in the Caucasian population 
worldwide, and its incidence is rising year after year. The most important reason for this 
increase is ultraviolet (UV) radiation, due to sun exposure and the use of tanning beds. 
 SC comprises melanoma and non-melanoma skin cancer (NMSC). The incidence of 
NMSC is much higher as compared to melanoma. Basal cell carcinoma (BCC), squamous 
cell carcinoma (SCC) and its precursors, actinic keratosis (AK) and Bowen’s disease (BD), 
represent the vast majority of NMSC. Melanomas form a smaller group of SC, however 
their mortality rate is higher. Although not all NMSC demonstrate metastatic potential, 
their treatment may lead to functional and cosmetic loss. To lower SC related mortality 
and morbidity, early detection is crucial. 
 Concomitant to the rise in SC prevalence, costs for SC care are rising, leading to a 
substantial burden on healthcare services.
In this introduction we will mainly focus on the most common types of SC: BCC, SCC, 
melanoma, and the pre-malignancies AK and BD.
1.1 Epidemiology 
Several studies with respect to the epidemiology of (pre-)malignancies of the skin have 
been performed. In spite of this, accurate figures on the incidence and prevalence of NMSC 
in the Netherlands are difficult to obtain. BCCs are only registered in one part of the 
Netherlands. Moreover, only the first histologically confirmed BCC or SCC is registered, 
although an extensive part of the population develops multiple SC. Pre-malignancies, e.g. AK 
and BD, are not included in national registries, therefore their actual incidence is unknown.
 BCC is the most common form of SC. In Australia, BCC and also other types of SC, 
form an enormous health care problem. A longitudinal study in a subtropical Australian 
population in 2009, showed an overall age-standardized incidence rate of BCC of 1,541 
people affected per 100,000 person-years at risk1. In the Netherlands, an approximately 
threefold increase in age-adjusted incidence rates has been noted between 1973 and 
20082. In 2008, one in five men and one in six women had developed a BCC before the 
age of 852.The predictions are that for the upcoming years the incidence will continue to 
increase2. 
 The chance of developing an additional BCC in patients with a previous BCC is almost 
30%, which, as described above, is probably a conservative estimate3. Male sex and age 
60 or over are associated with high BCC counts and patients with high numbers of AK are 
most likely to experience the highest number of BCC4. It has also been shown that BCCs 
occur more and more in younger patients, mainly in young women5.
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BCC on the head, trunk and on the limbs were strongly associated with high numbers of 
solar keratoses on these sites. 
 SCCs are more often seen in patients who chronically use immunosuppressive 
medication, e.g. transplant recipients22. The most common risk factors for melanoma 
besides UV exposure are family history, fair skin, multiple moles and chronic immuno-
suppression use23. 
1.3 Prevention
Since UV radiation is considered the most important environmental risk factor for the 
development of SC, primary prevention is based on the reduction of UV exposure, 
especially in childhood and adolescence. The World Health Organisation’s sun protection 
advice includes: the avoidance of sunlamps and tanning parlours, the limitation of 
exposure to midday sun, to watch for the UV-index, to use the shade wisely, to wear 
protective clothing and to use sunscreen24.  The preventative properties of sunscreen in 
various types of skin cancer have been studied. In a community-based randomised trial 
with a 2 by 2 factorial design, individuals were assigned to four treatment groups: daily 
SCC is the second most common SC. The incidence of SCC has increased over the last 
years, and is predicted to rise further to 2020 and reach a European Standardised Rate of 
46.9 per 100,000 inhabitants for males and 28,7 for females6. A 5-year relative survival 
curve, calculated over patients included between 1989 and 2008, remained stable over 
time6. 
 Since AK is mostly diagnosed clinically, incidence figures are difficult to assess. 
However, in a recent study conducted in the Netherlands, AK prevalence of 49% in men 
and 28% in women was found in a cohort of participants aged 45 years or older7. In a 
German study, a prevalence of 16.36% in men and 6.29% in women was found in the age 
group 61-70 years in a working population8. Epidemiological studies on the incidence of 
BD are scarce and outdated9. 
 The incidence of melanoma was assessed in a study performed in the Netherlands10. 
An increase in incidence was found in age-standardized incidence (ESR per 100.000 
person years) from 11.3 in 1989 to 21.7 in 2008. Furthermore, mainly due to improved 
awareness and early diagnosis, an increase in 10-year relative survival was found for both 
men and women over time. 
1.2 Risk factors
The rising incidence of SC is most likely caused by UV radiation due to increasing exposure 
to sun and tanning bed use. BCC is related to intermittent and intense sun exposure 
especially in childhood and adolescence11,12, whereas SCC is associated with cumulative 
sunlight exposure13. In melanomas, intermittent sun exposure and (severe) sunburn 
during childhood constitute high risk factors14 (table 1). In a large, multicentre case-control 
study it was found that subjects with a sun-sensitive skin type (Fitzpatrick I) had a 
statistically significant increased risk on developing BCC, SCC, and melanoma15. The 
presence of AK represents a marker of sun damage and increased risk of NMSC 
development16. 
 Other significant risk factors for BCC are higher age, red hair18, exposure to ionizing 
radiation, use of photosensitizing medication, chronic immunosuppression, HIV sero-
positivity and genetic syndromes e.g. nevoid basal cell carcinoma syndrome19. Most of 
these risk factors are also of importance in patients with SCC. However, SCC may also 
appear in chronically injured skin and ulcers20. For SCC, the presence of AK and BD form 
a risk factor, as they are pre-malignancies of SCC. Although AK and BD are not directly 
related with BCC, it has been demonstrated that a high number of solar keratoses confer 
a greater than 3-fold risk for BCCs of both the head and the trunk. BCC of the trunk have 
a particularly strong association with the number of reported sunburns and solar 
lentigines21. Another study demonstrated that patients with high numbers of solar 
keratoses were most likely to experience the highest BCC counts overall4. Moreover, 
Table 1  Association of the most important risk factors in the development of basal 
cell carcinoma, squamous cell carcinoma and melanoma.
Risk factor BCC SCC Melanoma
UV exposure:
sunburn (young age) ++ + ++
intermittent ++ + ++
cumulative + ++ +
phenotype ++ ++ ++
age +++ +++ +
male sex ++ ++ +
educational level + - +
immunosuppressives ++ +++ +
high dose PUVA ++ +++ +
smoking - ++ -
Abbreviations: basal cell carcinoma (BCC), squamous cell carcinoma (SCC), psoralen and ultraviolet A therapy 
(PUVA)
Modified from Holterhues C, de Vries E, Nijsten T. De epidemiologie van huidkanker: zorg om de zorg. Ned 
Tijdschr Dermatol. Venereol, 2009 sept;19(8):451-45517.
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Squamous cell carcinoma and Bowen’s disease 
SCCs mainly appear on the sun-exposed areas of the skin. Their clinical presentation may 
vary from a small nodule to a nodule with central ulceration and hyperkeratosis. Lesions 
may be reported as painful. 
BD presents as sharply demarcated scaly or crusted erythematous plaques. BD mostly 
occurs on the sun-exposed areas of the skin, but may also be seen on other body sites. 
BD may progresses to invasive disease if not treated20.
Actinic keratoses 
AKs also occur on the sun-exposed areas of the skin and present as scaly erythematous 
papules, which may vary in size from a few millimetres to nummular plaques. They may 
also have a brown or pink colour and are generally more easily felt, as rough lesions, than 
seen. 
 AKs can occur as single lesions or as multiple lesions, sometimes in close proximity 
(field AK). Lesions may spontaneously regress, recur or progress into SCC. The risk of 
progression of one single lesion into SCC is estimated from 0% to 0.075% per year28. In 
patients with a history of NMSC the rate of progression from AK to SCC is estimated 0.53% 
per lesion. However, most patients have multiple and recurrent AKs, the reason why AK 
can be seen as a chronic disease, making the risk on SCC higher.
Melanoma
Melanomas demonstrate various clinical features. They mostly appear as hyperpigmen-
tated nodules or macules. Complains as itching, bleeding, ulceration and pain may be 
present. 
Diagnosis 
BCC, SCC and BD are generally diagnosed by performing a diagnostic biopsy. In case of 
high clinical suspicion treatment can be started without a prior biopsy. Dermatoscopic 
examination can contribute in establishing the diagnosis of BCC, since it allows for 
visualization of arborizing telangiectasias29. In case of a biopsy, it should be noted that 
there may be disagreement between the histological subtype diagnosed by biopsy as 
compared to the histological results of the excision30,31. This is caused by sampling error, 
which means that the most aggressive part of the tumour is missed by the performance 
of a biopsy. The diagnosis of AK is a clinical diagnosis, in case of diagnostic doubt a biopsy 
should be performed.
 Pigmented lesions can also be judged with a dermatoscope. In case of suspicion of a 
melanoma a diagnostic excision with a margin of 2 mm must be performed32. Lesions 
should be excised completely, since incomplete excisions (e.g. diagnostic biopsy, shave) 
may lead to sampling error with respect to Breslow thickness, the most important marker 
for prognosis, thereby influencing the accuracy of pathological staging. 
application of a sun protection factor 15-plus sunscreen to the head, neck, arms, and 
hands, and beta-carotene supplementation (30 mg per day); sunscreen plus placebo 
tablets; beta-carotene only; or placebo only25. It was found that SCC but not BCC could 
be prevented by regular application of sunscreen. After a further 8 year follow-up it was 
found that BCC tumour rates tend to decrease, although not significantly26. 
 Secondary prevention is performed with the purpose of early detection and 
treatment, e.g. total body examination performed by a physician or the patient himself. 
1.4  Clinical presentation and diagnosis
Basal cell carcinoma 
The clinical presentation of BCC is dependent on the subtype. The most common types 
are nodular and superficial BCCs. Nodular BCC (nBCC) may present as a shiny pearly 
nodule with teleangiectasias and elevated edges. Crusting may be present overlying the 
central depression or the lesion may ulcerate. Most nBCCs occur on the face. Superficial 
BCC (sBCC) may present as well-circumscribed scaly erythematous papules or plaques, 
sometimes with small pearly papules forming a thin rolled border. sBCCs are mainly seen 
on the trunk and the extremities. In young patients sBCC is the most common BCC 
subtype. A third group is formed by infiltrative BCCs (iBCC), they are the least common 
type of BCC and present as shiny indurated, sometimes depigmentated nodules that may 
resemble a scar. Also less frequently seen are micronodular BCCs (mnBCC) which present 
as papules or slightly elevated plaques, they may clinically appear as nBCCs.   
 All BCC types may be pigmented. BCCs can be classified as low risk or high risk BCC 
(table 2).
Table 2  Prognostic factors basal cell carcinoma. 
low risk high risk
histological subtype non-aggressive  
(nodular, superficial)
aggressive  
(infiltrative, micronodular)
location trunk H-zone  
(eyes, ears, lips, nasolabial fold, nose)
size < 2 cm ≥ 2 cm
previous therapy primary tumour recurrent tumour
Modified from Kelleners-Smeets NWJ dHE, Beljaards RC, Ingels KJAO, Corten EML, Buis PAJ, et al. Evidence- 
based Richtlijn Basaalcelcarcinoom (modulaire update 2014)27.
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 For BD, also several therapeutic options are available. Cryotherapy, which is 
inexpensive and easily performed at the outpatient clinic. Topical 5-FU, PDT and surgical 
excision are also adequate therapies in BD. The choice of treatment is based on the 
clinical features of the tumour and the physical condition of the patient. 
 
Actinic keratosis
Since AKs have a risk of progression into SCC, treatment of all AKs is advised in the Dutch 
guideline36, especially in patients with multiple or field AKs. Treatment of AKs can be 
lesion- directed or field-directed (table 3). 
 Cryotherapy is the most common used lesion-directed treatment. It is performed with 
liquid nitrogen (-195.8 °C), most frequently used as an open spray method. The advantage 
of this therapy is that it is easy, non-expensive and effective37. The disadvantage is that 
healthy surrounding skin may also be destroyed. Moreover, cryotherapy may cause 
scarring and loss of pigmentation in the skin38. 
 Field-directed treatments like 5-FU, IMI, ingenol mebutate and PDT have the 
advantage of being more selective, thereby destroying only atypical cells, with better 
cosmetic outcomes. The comparison of (dis)advantages of these treatments are presented 
in table 3. In this table ingenol mebutate is not yet included, as this agent is only recently 
available in the Netherlands.
1.5 Treatment
Basal cell carcinoma
Several treatments are available for BCC. The treatment type depends on the BCC 
subtype, the size and the location of the tumour and patient characteristics. All BCC 
subtypes can be adequately treated with surgical excision with predetermined margins. 
A 3 mm margin is used for sBCC and nBCCs. In case of a tumour size >1 cm and/or an 
infiltrative or micronodular subtype a margin of 5 mm is preferred27. After excision, 
histological examination of the BCC subtype, as well as the excision margins is performed 
by a pathologist to assess peripheral clearance of the tumour. In case of incomplete 
excision a re-excision is recommended. Recurrent BCCs and high risk primary BCCs 
located in the head-neck region, may be indications for treatment with Mohs surgery33, a 
surgical technique by which the complete skin cancer can be excised, while doing 
minimal damage to surrounding healthy tissue. There are several additional treatment 
options, all of which have the disadvantage of lack of histological control. However, these 
therapies are non-invasive; they include imiquimod (IMI), 5-fluorouracil cream (5-FU), and 
photodynamic therapy (PDT). IMI is a topical immunomodulating cream, which is 
registered for the treatment of sBCC. The working mechanism is described as induction 
of pro-inflammatory cytokines and chemokines which eventually lead to the mounting 
of a profound T-helper mediated anti-tumour immune response34.  
 5-FU, a topical treatment for sBCC, is a chemical agent which inhibits thymidylate 
synthase, which is needed for DNA synthesis. 
 PDT is registered for the treatment of superficial- and nodular BCC. The first step is 
the application of the topical photosensitiser (5-aminolevulinic acid (ALA) or methyl ami-
nolevulinate (MAL)). After a three-hour incubation time, in which protoporphyrin IX (PpIX) 
is upregulated in the target cells, the treatment area is irradiated with a red light source. 
During light exposure, reactive oxygen species are produced and apoptosis is induced, 
leading to cell death of the tumour cells. 
 Occasionally destructive surgical techniques are used for low risk BCC including 
curettage and cautery, cryosurgery and carbon dioxide laser33. In specific cases, if other 
treatment options are deemed inappropriate, BCC can be treated with radiotherapy.
Squamous cell carcinoma and Bowen’s disease
Excision is the first choice of treatment in SCC. The margins of the excision are based on 
the type of tumour. Primary and low risk tumours are excised with a margin of 5 mm, 
recurrences and high-risk tumours with a 10 mm margin35. The distinction between high 
and low risk tumours is based on the size of the tumour, the location and aggressive 
pathological features. In patients who have inoperable tumours or who do not tolerate 
surgery, radiation therapy may be an appropriate alternative20. 
Table 3   Comparison of the advantages and disadvantages of the different treatment 
techniques for actinic keratosis (based on Dutch guideline).
based on: cryotherapy 5-FU imiquimod PDT Peeling/
laser
lesion characteristics
single lesion(s) **** *** *** ** *
multiple lesions ** **** **** **** ****
hypertrophic AK ** * * * *
patient characteristics
low compliance **** ** ** **** ****
high compliance ** **** **** ** **
****  = treatment of first choice
***  = best alternative after first choice treatment
**  = medium alternative
*  = not recommended 
Abbreviations: actinic keratoses (AK), 5-fluorouracil (5-FU)
Modified from Beljaards RC, Borgonjen RJ, Engelen JWM, Everdingen JJE, Marion AMW, Munte K, et al. 
Richtlijn Actinische keratose36.
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Skin cancer diagnosis and treatment in primary care
In the Dutch medical curriculum, courses in dermatology are most frequently taught 
during the Bachelors, followed by a (sometimes optional) clinical rotation in dermatology 
during the Masters48. With respect to GP trainees’ training in dermatology there is no 
national consensus, therefore this may vary per university48. As mentioned above, high 
numbers of patients with skin diseases present themselves to GPs, while the intensity of 
training programmes in dermatology is limited. Several studies, mostly international, have 
been performed to provide insight in the skills of GPs in diagnosing and treating SC. 
 It was found that GPs have difficulties diagnosing SC. In a study performed in Irish 
GPs a 54% agreement between the clinical diagnosis of the GP and dermatologist was 
found49. In this study, a total of 38 of the referred patients had pathologically proven skin 
malignancies. These were diagnosed accurately by the GP in 22% of patients49. 
 In Australia, a continent with an extremely high incidence of SC and a substantial 
contribution of GPs in skin cancer care, it was found that skin cancer physicians and GPs 
have the same overall sensitivity for diagnosing skin cancer, resp. 0.94 and 0.9150. In one 
of the few studies performed in the Netherlands, the sensitivity for the clinical diagnosis 
of a malignant lesion was 38% in lesions excised by GPs51. In the same study it was found 
that 4.7% of all excised lesions included pre-malignancies or malignancies. Furthermore, 
49.1% of lesions clinically diagnosed as (pre-)malignant were pathologically diagnosed as 
benign.  
 In previous European studies completeness of excisions performed by GPs showed 
a complete excision rate for BCC of 67.9%-79.8%, in SCC of 72.1%-85.5%, and 65.4% in case 
of melanoma52-54.  
Health care costs
The rising incidence of SC is associated by an increase in SC-related costs. In a study 
performed in the U.S. it was found that the average annual cost for SC increased from 
$3.6 billion in 2002-2006 to $8.1 billion in 2007-2011, an increase by 126.2%55. With these 
costs, NMSC is in the top five most costly cancers to Medicare in the U.S56. In Sweden an 
increase of 27% was seen in SC costs (including pre-malignancies and melanocytic naevi) 
from 2005 to 201157. The direct SC costs in 2011 were €102.2 million, the total indirect 
costs (e.g. production loss due to morbidity and mortality) €177.6 million57. In England 
future SC costs are estimated to be over £180 million in 202058.
In the Netherlands, 5-FU is available as a 5% cream and used twice daily until erosions of 
the skin appear. In AKs, IMI is used three times per week during four weeks. Four weeks 
after the end of the treatment the efficacy is evaluated. If necessary, the treatment should 
be repeated. 
 PDT is another form of field-directed treatment. It is performed in the hospital. The 
mechanism of action is the same as described for BCC. A disadvantage of this treatment, 
mainly in AK, is that it can be painful. For this reason, daylight PDT has become recently 
available. In daylight PDT the incubation time of the photosensitizer is shortened and 
daylight is used instead of red light, leading to comparable efficacy rates, but patients 
experience less pain39.
 A new therapy is ingenol mebutate. This is a topical treatment suitable for field AK. 
The mechanism of action is not fully elucidated, but seems to be based on induction of 
necrosis and the production of cellular cytotoxicity of residual cells40. 
 Furthermore laser, chemical peels, and surgical techniques as curettage, shave and 
dermabrasion can be used in the treatment of AKs. Surgical techniques are preferably 
used for single thick hyperkeratotic lesions. Laser is an effective but expensive treatment. 
The Dutch guideline recommends peels as an option for patients with a low compliance36. 
Melanoma
As mentioned previously, the diagnosis of melanoma is performed by a diagnostic 
excision with a 2 mm margin. In case the diagnosis of a melanoma is confirmed a 
therapeutical re-excision needs to be performed, with excision margins based on the 
Breslow thickness of the tumour41,42. 
1.6  Organisation and costs of skin cancer care
Organisation of care
In the Netherlands 554 dermatologists and 8865 general practitioners (GP) are registered43,44. 
The number of persons who will develop skin cancer in the Netherlands is estimated to be 
1 in 52 and one-third of these patients will develop at least a second primary skin cancer3. 
Pre-malignancies have not even been included in this calculation. At present most of 
these patients are treated by dermatologists45. However, in the Netherlands, patients visit 
their GP first with their health related questions. Performing this gatekeeper role, GPs may 
treat patients themselves, or in case of clinical doubt refer to a medical specialist. 
 In a study performed in the Netherlands, it was found that in 2009 more than 50% of 
dermatologists’ time was spent on skin cancer and skin neoplasms46. In a Dutch study 
performed in general practice, an annual increase of 7.3% in the demand for care due to 
skin lesions suspected of malignancy was found between 2001 and 201047. The benign : 
malignant ratio had changed from 17.5 : 1 in 2001 to 10.2 : 1 in 2010. 
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1.7 Aims and outline of this thesis
Aims of the thesis
As reported above, the number of patients with SC as well as the number of patients with 
multiple skin tumours is rising. However, data on the complete number of (pre-)
malignancies in this population remains unclear. 
 Besides the increasing burden on dermatological care, rising numbers of SC have an 
impact on the healthcare related costs. Early detection and adequate treatment may help 
to control this development. In the Dutch healthcare system, GPs act as gatekeepers, 
playing an important role in secondary prevention and adequate referral. 
 At present, the majority of SC patients are diagnosed and treated by dermatologists, 
thereby also spending substantial time on AK and low-risk BCC. The question rises 
whether these SC patients need to be treated in secondary or tertiary care centres. In 
near future it may be discussed to shift parts of low-risk SC care to primary care settings. 
Therefore, it is important to gain insight in the willingness of GPs to play a more extensive 
role in SC care. Also, to guarantee appropriate quality with respect to SC care, information 
is needed on the current knowledge and skills of GPs. 
 Evaluation of the cost and efficacy of common used SC diagnostics and treatment in 
hospital settings could contribute to improvement of SC care.
The following aims were formulated:
1. To investigate the tumour characteristics of NMSC populations in different hospital 
settings 
2a. To investigate the present role and skills of GPs in skin cancer care
2b. To explore the future role of GPs in SC care
3. To investigate the value of a diagnostic incision biopsy in BCC
4. To investigate patient characteristics, efficacy, and costs in patients with field AKs 
Outline of the thesis
In chapter 2 tumour characteristics are presented of patients with AK and BCC from 
university, as well as from general hospital settings.
Chapter 3 is devoted to the current and future role as well as the current skills of GPs in 
SC care. The results from a study on the role and willingness of GPs to participate in SC 
care are discussed, as well as the need for additional training. Furthermore, the necessity 
and quality of referrals made by GPs in a population of patients with skin tumours were 
investigated. Also, the surgical skills of GPs with respect to skin tumours were studied. 
In chapter 4 a study of the added value of a diagnostic punch biopsy in BCC in 
dermatological practice is presented.
In chapter 5 real life clinical data with respect to patient characteristics, efficacy, and 
costs in patients with field AK are shown and discussed.
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Introduction
The incidence of skin cancer (SC) is rising, placing a burden on health care systems 
worldwide1-3. The largest group of SC is formed by the non-melanoma skin cancers 
(NMSC), which mainly include basal cell carcinoma (BCC), squamous cell carcinoma (SCC) 
and its precursors. In the Netherlands, it has been found that 1 out of 5-6 people will 
develop at least one BCC during their life4. Furthermore, the 3-year cumulative risk for a 
subsequent tumour was found to be 44% for BCC and 18% for SCC5, resulting in high 
numbers of patients with multiple tumours. 
 Additionally, SC patients may be affected by premalignant lesions: Bowen’s disease 
(BD) and actinic keratosis (AK). In a recent Dutch study, conducted in the general 
population aged 45 years or above6, a prevalence of AK was found in 49% of male and 
28% of female participants. In a German study, conducted in a working population 
(employees of companies of various occupations), the AK prevalence was 16.4% in men 
and 6.3% in women in the age group 61-70 years7. 
 In daily practice nowadays, it is noticed that many patients present with multiple 
pre-malignancies and malignancies of the skin. However, their registration is incomplete. 
BCCs are often not registered and if they are, most registries only register the first primary 
histologically confirmed BCC. Moreover, BCCs may be treated without pathological 
conformation. Since AKs are diagnosed clinically, they are never registered. Consequently, 
data on the total number and combination of pre-malignancies and malignancies in SC 
patients are incomplete. 
 The aim of the present study was to provide insight into the severity of SC in a 
patient population with AK or BCC in both university and general hospitals and to 
describe the type and number of tumours in these patients. 
Methods
Patient characteristics
Patients in the present study were those who were included in an observational study 
on the cost-effectiveness of treatment of BCC and AK in the years 2010-2011. Patients 
included were cases of multiple (field) AKs located on the face and/or on the scalp or 
cases of nodular or superficial basal cell carcinoma(s). All patients were treated for the 
condition for which they were included. Patients were included at the outpatient clinics 
of four hospitals; two university hospitals and two general hospitals (Radboud University 
Medical Center, Leiden University Medical Center, Rijnstate Hospital, and Canisius Wilhelmina 
Hospital). Patients were included from a general outpatient clinic. Patients could be those 
with a previous history of SC or patients presenting for the first time with a skin tumour. 
Abstract
Background 
Skin cancer incidence is rising, placing a burden on healthcare systems worldwide. This 
problem may even be more extensive than expected, since registration of (pre)malignancies 
of the skin is poor. 
Objective 
To provide insight into the numbers of (pre)malignancies in patients with actinic keratosis 
(AK) or basal cell carcinoma (BCC) in 2 university and 2 general hospitals.
Methods 
The types and numbers of previous tumours and of tumours during a two-year follow-up 
were collected from 574 patients. 
Results 
Mean time between the first diagnosed (pre)malignancy and time of inclusion was 6.6 years. 
Overall, 60% had multiple types of (pre)malignancies. In BCC patients 61% had multiple BCCs, 
in patients with squamous cell carcinoma (SCC), 40% had multiple SCCs. The combination 
‘BCC and SCC’ occurred in 10%, ‘BCC and AK’ in 47%, ‘SCC and AK’ in 14%. 
Conclusion 
High numbers of patients with multiple (pre)malignancies were found in this patient 
population in university and general hospitals, which may well reflect the Dutch hospital 
population. We conclude that skin cancer patients are more extensively affected than 
was expected up till now. Consequently, the management of skin cancer may be in need 
of adaptation in near future and the question arises whether dermatologists have the 
capacity for providing care for all these patients. 
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Results
Patients were included in four hospital settings in the Netherlands. Two general hospitals 
and one university hospital were located in the eastern part of the Netherlands, whereas 
one university hospital was situated in the western part.  A total of 574 patients were 
included in this study, 369 (64.3%) were female and the mean age at inclusion was 66.5 
years (AK patients 70.6, BCC patients 61.6). Fifty-four percent of patients were included for 
AK, 45.6% for BCC. Of all the patients, 313 (54.5%) had (pre)malignancies of the skin prior 
to the start of the study. Of these patients, the mean time between their first diagnosed 
(pre)malignancy and inclusion was 6.6 years. A total of 333 (58.0%) patients were included 
in university hospitals. Three patients were transplant recipients.
History 
Patients with AK had a mean time of 6.8 years (SD 6.3, range 1-34) between their first (pre)
malignancy and inclusion, in BCC patients a mean time of 6.2 years (SD 5.4, range 1-29) 
was found. An overview of the number of (pre)malignancies prior to inclusion is provided 
in table 1. 
 To create an overview of pre-malignancies and malignancies (referred to as (pre)
malignancies)) in patients’ histories and during a two years follow-up (FU), data were 
collected from patient records and the correspondence of referring doctors (e.g. general 
practitioner, dermatologist, surgeon). 
 The following data were collected: patient’s age and sex, date of the first (pre)
malignancy, and the number and type of (pre)malignancies during history and a two year 
FU. All (pre)malignancies diagnosed at the start and during the study were registered as 
‘occurred during FU’. (Pre)malignancies registered as ‘history’ were those diagnosed 
before inclusion. In all patients, at least one total body examination was performed 
during FU. At least two FU contacts were scheduled for the observational study. 
 Except for AK, which is diagnosed clinically, only histologically proven primary 
tumours were recorded. Patients with genetic disorders leading to multiple skin cancers 
were not included in this study. All other patients with various types of co-morbidities 
were included to provide insight in regular daily clinical practice. As this study had an 
observational design, most patients with field AK or BCC in the participating hospitals 
were willing to participate and were included in the study, thereby representing the SC 
population visiting the dermatological out-patient department well.
Statistics
Data collection and analysis were performed using Statistical Package for Social Science 
(SPSS 20.0, IBM Corp, Armonk, NY). Only descriptive statistics were used to present 
information: percentages in case of nominal variables, mean and standard deviation in 
case of continuous variables. 
 In cases of AKs, the number of lesions was not always registered in the patient’s file. 
Therefore, we only registered if a patient had AK. AK numbers were not taken into the 
analysis. 
 Since data in the present study are collected from a selective patient population 
(hospital population), these numbers are not suitable for calculating incidence and 
prevalence. The outcome data were used to give an indication of the number and types 
of (pre)malignancies in a hospital population of patients with AK or nodular or superficial 
BCC. 
 Since data were collected in two different populations (AK and BCC patients), data 
are initially described for both groups separately, to provide insight into the different 
patient characteristics between these groups. 
 This study was approved by the ethics committee of all participating hospitals, all 
included patients gave consent to participate in this study. 
Table 1   Overview of number of tumours in patients with a previous history of (pre)
malignancies. (n(%))
Actinic keratosis  
(n = 192 patients)
Basal cell carcinoma  
(n = 121 patients)
0 tumours 1 tumour > 1 tumour 0 tumours 1 tumour > 1 tumour
BCC 110 (57.3%) 47 (24.5%) 35 (28.2%) 17 (14.0%) 34 (28.1%) 70 (57.9%)
SCC 146 (76.0%) 28 (14.6%) 18 (9.4%) 110 (90.9%) 5 (4.1%) 6 (5.0%)
BD 144 (75.0%) 29 (15.1%) 19 (9.9%) 105 (86.8%) 9 (7.4%) 7 (5.8%)
Melanoma 181 (94.3%) 11 (5.7%) - 114 (94.2%) 6 (5.0%) 1 (0.8%)
Dysplastic nevus 192 (100.0%) - - 116 (95.9%) 5 (4.1%) -
Other 113 (93.4%) 8 (6.6%) - 120 (99.2%) 1 (0.8%) -
Total 
malignancies* 
80 (41.7%) 52 (27.1%) 60 (31.2%) 10 (8.3%) 36 (29.8%) 75 (61.9%)
Number of 
different 
malignancies**
80 (41.7%) 77 (40.1%) 35 (18.2%) 10 (8.3%) 99 (81.8%) 12 (9.9%)
* Total number of all malignancies (BCC, SCC, Melanoma, other)
** Number of different types of malignancies (BCC, SCC, Melanoma, other)
Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Bowen’s disease (BD)
Other are: lymphoma, atypical fibroxanthoma and lentigo maligna
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 The combination ‘BCC and SCC’ occurred in 4.2% of patients included with AK and in 
4.6% of patients included with BCC, the combination ‘BCC and AK’ in respectively 28.2% 
and 43.9%,the combination ‘SCC and AK’ in respectively 10.3% and 3.8%, and the 
combination ‘SCC, AK and BD’ in respectively 3.5% and 1.9%. 
Overall (history and FU)
The total number of malignancies in these hospitals, during history and FU time together, 
are provided in table 3. Patients with higher numbers of multiple tumours were more 
frequently seen in university hospitals. 
 Overall and for both AK- and BCC-group combined, over 40% of all patients had 
more than one BCC, 5.8% had more than one SCC, and 6.8% more than one BD (table 4). 
Multiple melanomas or dysplastic nevi occurred in one patient. A total of 59.9% of all patients 
had more than one type of premalignancy and/or malignancy of the skin (table 4). 
 The combination ‘BCC and SCC’ occurred in 9.6% of patients, ‘BCC and AK’ in 47.4%, 
‘SCC and AK’ in 13.9%, and the combination ‘SCC, AK and BD’ in 7.3%.
 Of all patients with BCC, 61.3% (242/395) had more than one BCC (max. 33). Of all 
patients with SCC 40.2% (33/82) had more than one SCC (max. 17).
The combination ‘BCC and SCC’ occurred in 16.7% of patients included with AK and in 
11.6% of patients included with BCC, the combination ‘BCC and AK’ in respectively 51.6% 
and 72.7%, the combination ‘SCC and AK’ in respectively 29.2% and 10.7%, and the 
combination ‘SCC, AK and BD’ in respectively 16.7% and 5.8%. 
Follow-up
In patients included with AK, the mean FU time appeared to be 22.0 months (SD 4.5, 
range 3-24); in patients included with BCC this was 23.5 months (SD 3.6, range 3-24). An 
overview of the number of (pre)malignancies during FU is provided in table 2. 
Table 2   Overview of number of tumours during follow-up. (n(%))
Actinic keratosis  
(n = 312 patients)
Basal cell carcinoma  
(n = 262 patients)
0 tumours 1 tumour > 1 tumour 0 tumours 1 tumour > 1 tumour
BCC 224 (71.8%) 45 (14.4%) 43 (13.8%) 0 (0.0%) 116 (44.3%) 146 (55.7%)
SCC 280 (89.7%) 23 (7.4%) 9 (2.9%) 250 (95.4%) 10 (3.8%) 2 (0.8%)
BD 273 (87.5%) 27 (8.7%) 12 (3.8%) 234 (89.3%) 21 (8.0%) 7 (2.7%)
Melanoma 310 (99.4%) 2 (0.6%) - 259 (98.9%) 3 (1.1%) -
Dysplastic nevus 312 (100.0%) - - 260 (99.2%) 2 (0.8%) -
Other 311 (99.7%) 1 (0.3%) - 260 (99.2%) 2 (0.8%) -
Total 
malignancies* 
202 (64.7%) 59 (18.9%) 51 (16.4%) 0 (0.0%) 111 (42.4%) 151 (57.6%)
Number of 
different 
malignancies**
202 (64.7%) 97 (31.1%) 13 (4.2%) 0 (0.0%) 243 (93.5%) 17 (6.5%)
* Total number of all malignancies (BCC, SCC, Melanoma, other)
** Number of different types of malignancies (BCC, SCC, Melanoma, other)
Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Bowen’s disease (BD)
Other are: lymphoma, atypical fibroxanthoma and lentigo maligna
Table 4   Overview of number of tumours overall (history and follow-up). (n(%))
AK and BCC together  
(n = 574 patients)
0 tumours 1 tumour > 1 tumour
BCC 179 (31.2%) 153 (26.7%) 242 (42.1%)
SCC 492 (85.7%) 49 (8.5%) 33 (5.8%)
BD 466 (81.2%) 69 (12.0%) 39 (6.8%)
Melanoma 550 (95.8%) 23 (4.0%) 1 (0.2%)
Dysplastic nevus 568 (99.0%) 5 (0.9%) 1 (0.2%)
Other 562 (97.9%) 12 (2.1%) -
Total malignancies* 139 (24.2%) 165 (28.7%) 270 (47.1%)
Number of different malignancies** 139 (24.2%) 359 (62.5%) 76 (13.2%)
Number of different (pre)malignancies*** - 230 (40.1%) 344 (59.9%)
* Total number of all malignancies (BCC, SCC, Melanoma, other)
** Number of different types of malignancies (BCC, SCC, Melanoma, other)
*** Number of different types of (pre)malignancies 
Basal cell carcinoma (BCC), actinic keratosis (AK), squamous cell carcinoma (SCC), Bowen’s disease (BD)
Other are: lymphoma, atypical fybroxanthoma and lentigo maligna
Table 3   Number of patients with multiple malignancies (all malignancies together).   
(n(%))
0 1-5 6-10 >10 total
General hospital 77 (32.0%) 153 (63.5%) 9 (3.7%) 2 (0.8%) 241
University hospital 62 (18.6%) 184 (55.3%) 51 (15.3%) 36 (10.8%) 333
Overall 139 (24.2%) 337 (58.7%) 60 (10.5%) 38 (6.6%) 574
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 As mentioned previously, data in the present study are based on a selective 
population and the results cannot be extrapolated to the whole skin cancer population. 
However, since appropriate SC registries are lacking, a population wide study based on 
cancer registries may not provide sufficient data to obtain a complete overview on all 
(pre)malignancies in our patient population. In our study, 574 patients from four hospital 
locations were included during a period of two years. As two general and two university 
hospitals participated, our results may reflect the situation with respect to characteristics 
of the patient population seen in West-European dermatological practices. 
 A potential limitation of our study might be that only patients with superficial and 
nodular BCC or multiple AKs were included. Furthermore, patients had various years of 
previous history and not all patients were followed during 24 month FU. However, these 
data do present an overview of the real life situation of these patients. If only a selection 
of years was included in the history data, this would not reflect the severity of this 
population as it appears to be in clinical practice, therefore we chose to use the full 
number of years in history and the total number of tumours. 
Conclusion
Overwhelming numbers of patients with AK or BCC included in our study appeared to 
exhibit multiple (types of) pre-malignancies and/or malignancies of the skin. 
 Since these patients were included in four hospitals and were only followed during a 
short timeframe, the total number of severely affected patients will be much higher in 
the whole Dutch hospital-based SC population. 
 Consequently, the management of SC may be in need of adaptation in near future 
and the question arises whether hospital based dermatologists have the capacity for 
providing care for all these patients. Reimbursement should be well correlated to the 
severity of the SC patients in hospital settings.  Additionally, those involved in SC care 
need to be aware of the fact that patients who present themselves with a first (pre)
malignancy, may well have additional and future lesions, therefore total body examination 
and FU are recommended.
Discussion
An overwhelming number of patients included in the present study had multiple pre- 
malignancies and/or malignancies of the skin. Overall, almost 60% had more than one 
type of pre-malignancy and/or malignancy. Forty-seven percent had more than one 
malignant skin tumour. These numbers may be higher than those found in a general 
population, since inclusion criteria for our study were the presence of BCC or multiple AKs 
at the start of FU. Furthermore, it may be expected that patients with multiple AKs have a 
certain extend of actinic damaged skin, which makes them more at risk for the 
development of additional (pre)malignancies8. Multiple BCCs and the combination ‘AK 
and BCC’ occurred in almost half of the patients. In a recent review performed by Flohil et 
al. (2013) the pooled proportion for a subsequent BCC in a patient with a previous BCC 
was 29.2%, this percentage was based on previously performed studies9. The higher 
numbers found in the present study may be explained by the selective study population 
and by an increase in SC incidence in recent years. As the incidence of SCC and BD is 
lower, multiple tumours of these types occurred less frequent, but still in more than 5% of 
patients, whereas the combination ‘SCC and AK’ occurred in almost 14%. Furthermore, 
multiple SCCs and BD were found more frequently and in higher numbers in patients in 
the AK population. The latter findings may not be surprising, since AKs and BD are 
considered to be precursors for SCC10. Additionally, AK patients included in our study 
where those eligible for field therapy, indicating that these were patients with multiple 
AK, which is a risk factor for the development of SCC11, also the existence of AK for 
multiple years could increase the risk of progression12. 
 The combination of AK and BCC occurring in the same patient may be explained by 
sun exposure leading to both these tumours. It was found that the occurrence of 
(multiple) AK is associated with a higher risk in the development of BCC8,13.  Patients with 
multiple dysplastic nevi or melanomas were rarely observed in this study. This is probably 
caused by our inclusion criteria, focussed on NMSC. In previous studies, in patients with 
melanoma, the number of patients with multiple melanomas was higher14,15. 
 Patients with high numbers (>5) of malignancies were mainly included in university 
hospitals. These findings may be explained by the fact that in clinical practice it is 
common to refer severely affected patients to university hospitals for more specialized 
care. However, it should be noted that only a few of the patients in our study were organ 
recipients and that patients with genetic disorders leading to SC were excluded. 
 More than half of the patients had a previous history of (pre)malignancies and the 
mean time between the first tumour and inclusion was 5.1 years for general hospitals and 
7.3 years for university hospitals. These numbers indicate that a substantial number of 
patients have a chronic skin cancer problem and may be in a life time follow-up, which 
contributes to high costs in health care. 
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Introduction 
Recent studies show a rapid increase in the incidence of skin cancer (SC)1-3, which will 
lead to a burden on dermatologists’ practices and healthcare costs.
 Melanomas form the smallest, but most fatal, group of SCs. Non-melanoma skin 
cancer (NMSC) includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), 
and the premalignant lesions actinic keratosis (AK) and Bowen’s disease (BD). Besides 
mortality, NMSC contributes to cosmetic and functional morbidity. Both early treatment 
and primary and secondary prevention are of great value to lowering SC-related mortality 
and morbidity. As in many countries, general practitioners (GPs) are the first to see a 
patients with SC. The present study aims to assess GPs’ attitude towards their role in SC 
prevention, diagnostics and treatment, and information on their need for education.
Methods
This study was performed in 2010-12. Anonymous questionnaires were sent to 552 GPs in 
the region of Nijmegen, the Netherlands. 
 The questionnaire contained 17 dichotomous questions, 11 multiple-choice questions, 
four five-point Likert scales (range: never to always) and four essay questions. These were 
divided into the following. Section 1 containing questions concerning self-assessment of 
knowledge of AK, BD, BCC, SCC and melanoma (table 1). Sections 2-4 contained questions 
concerning diagnosis and treatment of AK, BCC and SCC, including diagnostics used, 
number of referrals, reason for referral, type of known and used treatments, follow-up, 
guideline use and total body examination (TBE). Section 5 contained questions 
concerning risk factors, prevention, and GPs’ view on their future role in SC care.
 Statistical analysis of the results was performed using SPSS for Windows (version 16.0; 
IBM, Armonk, NY, USA). 
Results
In total 268 GPs returned the questionnaire (49% response rate). 
An overview of GPs’ need for knowledge and the possible influence of education on SC 
treatment is provided in table 1. 
Actinic keratosis
Seventy-five percent of respondents believe that AK treatment is a task for GPs. Half of the 
respondents often/always treat patients with AK themselves. Only 3.7% would never refer 
a patient with AK to a dermatologist. The most common reason for referral was suspicion 
of SCC. Table 1 provides an overview of AK treatments used by GPs.  
Abstract 
Background 
Given the increase in skin cancer (SC) it seems inevitable that general practitioners (GPs) 
will play a larger role in SC care in near future. 
Objectives 
To obtain insight into the opinion of GPs with respect to their role in SC care, and their 
SC knowledge and skills.  
Methods
A self-administered questionnaire was sent to GPs in the region of Nijmegen, the 
Netherlands. 
Results
In total 268 GPs (49%) responded. An overwhelming majority were willing to extend their 
role in SC care. Furthermore, we noted the following results:  
(i) > 50% of GPs request additional SC knowledge; (ii) GPs often treat actinic keratosis (AK) 
themselves, primarily with cryotherapy; (iii) > 50% would treat (low-risk) basal cell carcinoma 
(BCC) after additional training; (iv) only a few GPs are familiar with BCC guidelines; (v) the 
majority of patients with high-risk SC are referred to dermatologists; (vi) only a few GPs 
perform total body inspection and palpation of lymph nodes; and (vii) a large number of 
GPs inform their patients on risk factors in SC development. 
Conclusion
Most GPs are willing to extend their role in SC care; however, more training is requested 
and the usage of guidelines should be encouraged. Those willing to extend their role 
should focus on improving their clinical diagnosis of skin tumours, treatment of low-risk 
skin (pre)malignancies, including field-directed treatment of AK and noninvasive 
treatment of BCC, and on prevention.
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Basal cell carcinoma
Around 20% of GPs were of the opinion that treatment of BCC should be performed by 
a GP; 33.2% indicated that they would treat only low-risk BCCs. In case of suspicion of 
BCC, 73.0% would refer to a dermatologist, 9.7% would take a biopsy and refer afterwards, 
and 42.2% would excise the BCC. Thirty-four percent would perform TBE. Imiquimod and 
(referral for) photodynamic therapy are used by 9.3% of GPs. Twenty-seven percent are 
familiar with the BCC guidelines. 
Squamous cell carcinoma
Only 3% of respondents were of the opinion that SCCs should be treated by a GP. In case 
of suspicion of an SCC 88.4% would refer to a dermatologist, 13.1% would take a biopsy 
and refer afterwards, and 13.1% would excise the SCC. One fifth would perform TBE, and 
13.1% would palpate the lymph nodes. 
Prevention and risk factors
Most GPs (93.7%) see SC as a health problem in which they should play a role, while 86% 
would like to play a larger role in SC care.
 In total 93% of GPs indicated that they were familiar with the risk factors for SC 
development, whereas 70.5% would like to have more knowledge on risk factors. Only 1.3% 
never inform patients on risk factors. 
Discussion 
An overwhelming majority of GPs are willing to play a significant role in SC care; however, 
our results also demonstrate a high need for additional education and training. 
 Our survey demonstrates that after additional education, a larger number of GPs 
would treat BD, BCC and SCC. However, GPs remain reluctant to treat melanomas. This 
could be explained by the higher mortality rate caused by melanomas4, and is in 
agreement with the Dutch melanoma guideline, which advices GPs to refer patients with 
suspicion of a melanoma to a dermatologist5. The number of GPs who would treat AK 
after education is lower than that ‘before education’. This is probably because most GPs 
already treat AKs. 
 Only 3.7% of GPs would never refer a patient with AK to a dermatologist. Most GPs 
use only cryotherapy, which is suitable mainly for solitary AK6. As 75.4% of GPs agree that 
AK treatment is a task for the GP, field treatment for AKs would be a point of interest for 
education.
 As the majority of GPs participating in this study were not widely familiar with the 
usage of guidelines, with the treatment options for low-risk tumours, or with the 
performance of diagnostic biopsies, education in BCCs should focus on these aspects. 
Table 1  General practitioners’ need for knowledge, treatment skills for skin cancer, 
and knowledge and usage of actinic keratosis treatment.
Of which (pre) malignancy would you like to have more knowledge?
Actinic keratosis 111 (41.4%)
Bowen’s disease 213 (79.5%)
Basal cell carcinoma 121 (45.1%)
Squamous cell carcinoma 162 (60.4%)
Melanoma 149 (55.6%)
Which (pre) malignancy do you treat yourself?
Actinic keratosis 239 (89.2%)
Bowen’s disease 22 (8.2%)
Basal cell carcinoma 92 (34.3%)
Squamous cell carcinoma 18 (6.7%)
Melanoma 8 (3.0%)
Which (pre) malignancy would you treat if you had more knowledge of it?
Actinic keratosis 151 (56.3%)
Bowen’s disease 113 (42.2%)
Basal cell carcinoma 139 (51.9%)
Squamous cell carcinoma 53 (19.8%)
Melanoma 6 (2.2%)
Which treatment for actinic keratosis do you know?
Cryotherapy 268 (100%)
Imiquimod 96 (35.8%)
5-FU cream 168 (62.7%)
Photodynamic therapy 76 (28.4%)
Other 10 (3.7%)
Which treatment for actinic keratosis do you use yourself?
Cryotherapy 248 (92.5%)
Imiquimod 24 (9.0%)
5-FU cream 43 (16.0%)
Photodynamic therapy 0 (0.0%)
Other 10 (3.7%)
Data are n (%), based on responses from 268 general practitioners.
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Because of the metastatic potential of SCCs we agree that education on SCC should focus 
mainly on diagnostics, so GPs can play a role in early detection and referral7.  At present 
there is no Dutch guideline describing whether GPs should treat BCC or SCC in primary 
care. 
 The finding that TBE or palpation of lymph nodes is performed in only a few patients 
is worrisome. It is well known that SC also occurs on parts of the skin that are not 
frequently exposed to ultraviolet (UV) radiation8. Lack of time could be an important 
reason for GPs not to perform TBE9. Most GPs inform patients about risk factors. This is 
important because it has been proven that UV protection advice given by a GP improves 
sun protection in patients10. 
 A potential limitation of this study is that GPs were not asked about their years of 
experience or special interest. With a response rate of 49%, data on half of the selected 
GPs are missing. Although our data were collected in one specific region, it consisted of 
rural areas and large cities, and thus may provide a proper representation of the rest of 
the Netherlands. 
Our results have implications for clinical practice. It is of great value that most GPs would 
like to contribute to SC care; however, more education is needed. Training in recognition 
of the most common (pre)malignancies might promote early detection, which may be 
useful in secondary prevention. Furthermore, the use of a diagnostic biopsy may support 
the diagnostic process. With respect to treatment, progress could be made by teaching 
GPs about field-treatment in patients with AK. Additionally, GPs may be educated in the 
use of different treatment modalities for low-risk BCC and guideline use. Furthermore, 
GPs are of great importance in primary SC prevention, which is easy to learn and easy to 
perform. 
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Introduction
Skin cancer (SC) is a public health problem of increasing magnitude among fair-skinned 
populations worldwide, and it is responsible for an increasing contribution to health care 
costs1,2. The occurrence of SC at young age3,4 and the development of multiple tumours 
in many SC patients contributes to this problem5. A recent study showed that almost one 
in 5 persons will develop SC6. 
 Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and the premalignancies 
Bowen’s disease (BD) and actinic keratosis (AK) belong to the group of non-melanoma 
skin cancers (NMSC). In these skin malignancies, the mortality rate is low; however, 
morbidity and disfigurement may be caused by excision of large tumours in functional 
and visible areas. The incidence of melanoma is much lower4,7, but these tumours are 
responsible for the highest mortality rate. Treatment of BD and high risk AKs, especially in 
those with multiple lesions (e.g. field cancerisation), is recommended to eliminate the risk 
of evolution into invasive SCC8. Early detection may lower SC associated morbidity and 
mortality.
 Most skin cancer presents in primary care, and an important determinant of outcome 
may be initial recognition and management of the lesion. Previous studies have shown 
that general practitioners (GPs) have difficulties in diagnosing various types of skin 
diseases, including SC9-11. A study performed in the U.K. showed that 81% of malignancies 
sent for pathological analysis, was treated by dermatologists and 2% by GPs, the others 
were treated by other hospital physicians12. The latter may indicate that GPs refer high 
numbers of patients to dermatologists. The aim of our study was to investigate the 
necessity and quality of referrals made by GPs in a population of patients with skin 
tumours.
 
Methods
Study population
We collected all referral letters sent by GPs of patients who were referred with the 
diagnosis of a possible skin tumour to the department of Dermatology of the Radboud 
University Nijmegen Medical Centre (RUNMC) in the period from January 2008 to 
November 2010. Selection was based on the final diagnosis of a malignant or benign 
tumour in the hospital’s registration system. This computerised system is able to perform 
a patient selection based on a patient’s final diagnosis. Only few patients who were 
incorrectly diagnosed may be missed in our inclusion. Of all patients, referral letters, 
dermatological charts (filled out by the dermatologist or dermatology resident (DR)), and 
pathological results (when available) were collected. 
Abstract  
Skin cancer (SC) is common among white populations and rapid increases in incidence 
are being observed in many countries, leading to a large burden on healthcare systems. 
Unnecessary referrals from general practitioners (GPs) may contribute to this burden. 
The aim of this study was to analyse the quality of referrals from GPs of patients with skin 
tumours. Referral letters for 734 patients were collected. The proposed diagnoses were 
compared with definitive diagnosis made by dermatologists.
 In 44.5%, lesions appeared to be benign. Malignant skin tumours were poorly 
recognized by GPs and seborrheic keratoses were often mistaken for naevi (33.6%). 
Furthermore, with total body examination, dermatologists found 111 additional malignant 
lesions. We discussed several recommendations to minimize unnecessary referrals as well 
as the future role of GPs in SC care. 
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Diagnostics
Overall, 327 (44.5%) of the lesions, which were reason for referral appeared to be benign, 
204 (27.8%) were malignant, and 204 (27.8%) premalignant. Of the 255 lesions referred as 
malignant, 22.4% was diagnosed as premalignant and 25.1% as benign. Of all lesions 
referred as benign, 63.9% was diagnosed as benign. A cross tabulation of GPs’ diagnosis 
at referral and the final diagnosis presents an overview of the most occurring diagnostic 
errors made in these referrals (table 2). Additionally, positive predictive values (PPV) for 
GPs’ diagnosis at referral were calculated (table 3). 
 In 18.3% of the referrals a diagnosis was missing, the correct diagnosis was mentioned 
in 39.8% of letters. In 1.2% a diagnostic biopsy was taken by the GP prior to referral.
Non-melanoma skin cancer
GPs referred 188 patients with the possible diagnosis of a BCC. Ninety-one of these were 
finally diagnosed with a BCC, 11 with SCC, 34 with AK, one with BD, one melanoma, and 
45 with benign lesions. Of 153 patients who were ultimately diagnosed with BCC, 29 were 
referred without a diagnosis, and 16 with the question ‘malignant’. Out of 38 SCCs, 6 were 
referred as SCC. None of the 13 BD was referred with this diagnosis.  
 As compared to the pathologic diagnosis, dermatologists and DRs mentioned the 
correct diagnosis of a BCC in 95.4%, a SCC in 55.3%, and a BD in 30.8%. Additional PPVs 
were calculated (table 3). 
The following data were recorded:  
(1)  socio-demographic data including gender and age, 
(2)  description of the lesion, 
(3)  the number of diagnostic biopsies, 
(4)  the referral diagnosis, 
(5)  listed number; and 
(6)  location of (additional) lesions found by dermatologist or DR. 
The diagnoses at referral were compared with the pathological diagnoses. If no additional 
pathological analysis was performed, the clinical diagnosis made by the dermatologist or 
DR was used as the final diagnosis. If necessary, mainly in case of a pigmented lesion or 
BCC, dermatologists or DRs made use of a dermatoscope. Since the RUNMC is a training 
hospital, many clinical diagnoses of DRs were confirmed by a supervising dermatologist. 
In case a differential diagnosis was proposed, the first diagnosis mentioned was used in 
the analysis. 
 A diagnosis was defined as ‘correct’ when the diagnosis of the GP was in line with 
the diagnosis of the dermatologist and DR, or (if available) with the pathologic results. 
The differential diagnoses of the dermatologists and DRs were defined as ‘correct’ when 
they were in line with the pathological diagnosis. Therefore, the dermatologists’ and DRs’ 
diagnoses could only be verified in case a pathologic result was available; mainly in 
malignancies and some premalignancies.  
Data analysis
Statistic analysis was performed using the Statistical Package for Social Sciences (SPSS®) 
for Windows (version 20.0). Only descriptive statistics were used. 
Results
A total of 734 referral letters were collected from patients referred by GPs to the 
department of Dermatology at the RUNMC. The population consisted of 325 men (44.3%) 
and 409 women (55.7%), with a mean age of 58.3 years.
Location and number of lesions
Over 90% of patients were referred by their GP with one suspicious lesion. In < 10% the 
GP discovered > 1 lesion. Of all lesions, 61.0% was located on the face or scalp, 29.3% on 
the trunk or extremities and 5.9% on multiple body parts. In 3.8% the lesion location was 
not mentioned in the referral letter.
 By performing total body examination, dermatologists and DRs diagnosed 234 
additional premalignant and malignant lesions, including AKs, BD, dysplastic naevi, BCCs, 
SCCs, melanomas, and atypical fibroxanthoma (table 1). 
Table 1   Additional lesions found by dermatology resident or dermatologist after 
referral by general practitioner. Total of 146 patients with additional lesions 
(min. 1 and max. 20 per patient).
Head/neck Limbs Trunk Total number  
of lesions
Premalignancies
Actinic keratosis 75 14 15 104
Dysplastic naevus 0 0 5 5
Bowen’s disease 9 3 2 14
Total 123
Malignancies
Basal cell carcinoma 36 12 48 96
Squamous cell carcinoma 6 0 2 8
Melanoma 1 0 4 5
Atypical fibroxanthoma 2 0 0 2
Total 111
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Pigmented lesions
Forty-two of 125 of the finally diagnosed seborrheic keratosis were referred as (atypical) 
naevi. Furthermore, in 2 out of 8 melanomas and of 62 out of 102 benign naevi the correct 
diagnosis was mentioned in the referral letter. 
 As compared to the pathological diagnosis, dermatologists and DRs mentioned 
the correct diagnosis of a melanoma in 62.5% and a dysplastic naevus in 100%. Additional 
PPVs were calculated (table 3). 
Lesion description 
In 15.4% of the referrals, GPs added an adequate lesion description by using derma- 
tological terminology. In 24.0%, a lesion description was missing, in 39.5% the word ‘spot’ 
was used as a description, in 5.3% the word ‘lesion’, and in 15.8% the description: ‘looks 
like’ was used.  
Discussion
The present study provides insight in the quality of GPs’ referrals of patients with skin 
tumours, and their ability to differentiate between malignant and benign skin lesions. 
 Forty-four percent of all referred patients had benign tumours. Therefore, the 
question arises whether these referrals were really necessary, and if these numbers might 
be reduced in the future. 
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Table 3   Positive predictive values of general practitioners’ (GPs) diagnosis as 
mentioned in the referral letter and of dermatologists and dermatology 
residents (DR) prior to pathologic results.
Positive predictive values
Diagnosis GP, % dermatologist and DR, %
Basal cell carcinoma 48.4 72.6
Squamous cell carcinoma 31.6 65.6
Actinic keratosis 73.5 Not applicable 
Bowen’s disease 0.0 28.6
Melanoma 66.7 100.0
Seborrheic keratosis 82.1 Not applicable
Naevus/lentigo 57.9 Not applicable
Dysplastic naevus 0.0 20.0
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A possible limitation of our study may be that, in case of a differential diagnosis, only 
the diagnosis listed first was included in our analysis. Therefore, in some cases the GP or 
dermatologist and DR could have mentioned the correct diagnosis, but not first in line. 
Additionally, it should be noted that GPs do not always have a diagnosis for a skin lesion, 
and sometimes only refer suspicious lesions with the question ‘malignant?’, or without a 
question or diagnosis, therefore, ‘malignant?’ and ‘diagnosis missing’ were also added to 
our cross tabulation. We also included benign tumours to establish a complete overview 
of (unnecessary) referrals made in the full array of skin tumours.
On the basis of our study, we conclude that referrals of patients with skin tumours could 
be optimized. With the increasing incidence of SC, it is worthwhile to reduce the number 
of unnecessary referrals, to gain more capacity for patients in need of specialist care, e.g. 
reducing the number of referrals of benign lesions may lead to a decrease of almost 50% 
of patients referred with skin tumours.   
 Therefore, adequate training in clinical tumour characteristics of most common SC, 
and more frequent use of additional diagnostic techniques are worthwhile to gain 
appropriate competency in GPs. With the rising numbers of SC the question arises 
whether more specialised SC care performed by dermatologists is needed in primary 
care. Another solution might be the training of GPs with a special focus on dermatology 
to contribute to low key dermatological care. In Australia this concept is already in use, as 
SC is a major health problem in the fair-skin population of this country, thereby leaving 
more capacity for dermatologists to treat severely affected patients.  
 At present, GPs could contribute to optimise their referrals by adding appropriate 
dermatological lesion descriptions in their referral letters and by total body examination 
in patients with suspicious lesions. 
 With respect to NMSC, we found that GPs made the diagnosis of BCC in 188 of 734 
referrals (PPV 48.4%); 45 of these lesions were diagnosed as benign. The fact that the 
referral diagnosis of BCC was commonly used for other tumours may be explained by the 
fact that BCCs are more common than other malignancies4,7,13 and therefore BCC might 
be the first diagnosis a GP thinks of in these cases. Furthermore, it was also found that 
dermatologists and DRs were also less accurate in the diagnosis of SCC and BD, meaning 
that these tumours are probably more difficult to recognise14. 
 Almost 1/3 of SCCs was referred with the diagnosis of BCC. Given the fact that BCCs 
do not metastasise, whereas SCCs have the potential to do so, this may have the effect 
that patients with a SCC are not seen by a dermatologist with the urgency needed. In this 
study, only a few GPs provided an adequate lesion description (15.4%) or performed a 
biopsy (1.2%). In case of a misdiagnosis (e.g. SCC referred as BCC), an adequate lesion 
description may help the dermatologist to triage the correct level of priority for a hospital 
appointment. The encouragement of biopsy use in primary care may be worthwhile 
since it may lower the number of unnecessary referrals and contribute to the decision 
of the urgency of a referral. Furthermore, the performance of a biopsy may provide 
immediate reflection on their differential diagnosis, which could be of educational value. 
On the other hand, in case of a suspicious lesion, a dermatologist might perform an 
excision without previous biopsy, in which case referral without biopsy would save 
pathological costs.   
 In pigmented lesions GPs only recognized 25.6% of seborrheic keratosis (SK), although 
they are very common. Thirty-four percent of these SK were diagnosed as (atypical) naevi, 
a misdiagnosis which is often made15,16. Furthermore, only 2 out of 8 melanomas and 
62 out of 102 benign naevi were correctly diagnosed. This might indicate that GPs have 
difficulty in differentiating between pigmented lesions. There are some studies which 
indicate that dermatoscopy would be of additional value for GP17,18. This may suggest that 
dermatoscopy may help GPs in differentiating SK form other pigmented lesions, which might 
reduce unnecessary referrals. However, appropriate training and frequent use are necessary 
for adequate dermatoscopy performance and the question may arise whether GPs would 
make sufficient use of dermatoscopy to gain its additional value.
 The number of additional lesions found in these patients is alarming, and proves 
the fact that many SC patients develop more than one lesion. The distribution of SC over 
the body surface has been described in several studies, showing that SC not only appears 
on the chronically sun-exposed areas of the skin4,19,20, which pleads for total body 
examination. In a study of Terril et al.21, additional (treatment requiring) skin lesions were 
detected in 67% out of 100 referred patients, 34 of the additional lesions were localized 
on sites covered by clothing. Therefore, we conclude that total body examination is not 
performed on a large scale, although it would lead to early SC detection. An explanation 
of the fact that GPs do not perform full body examination in all cases, could be 
unawareness of the lesion distribution over the body surface or lack of time. 
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Introduction 
The incidence of skin cancer is increasing in the fair-skinned population worldwide and 
increasing the burden on health care delivery systems1-3. 
 The most common types of skin cancer are basal cell carcinoma (BCC), squamous 
cell carcinoma (SCC), and melanoma. BCCs and SCCs, together with the premalignant 
actinic keratosis (AK) and Bowen’s disease (BD), comprise the group of non-melanoma 
skin cancer (NMSC). NMSC has the highest incidence. Melanomas are responsible for the 
highest skin cancer related mortality4. 
 For the treatment of AK, BD, and BCC (depending on the subtype), topical agents can 
be used, depending on the diagnosis; this can be imiquimod, 5-fluorouracil cream or 
ingenol mebutate. Another possibility are destructive procedures such as cryotherapy. 
Treatment modalities for NMSC are many (e.g. photodynamic therapy, radiotherapy, 
topical treatments, curettage), but excisional surgery is the mainstay of skin cancer 
management5.
 In many countries skin cancer patients initially present themselves in primary care 
settings. However, in many countries the majority of skin malignancies are treated by 
dermatologists6. In case general practitioners (GPs) excise skin cancer, it was found that 
the rate of complete excisions was lower as compared to dermatologists7, and there were 
low rates of previous biopsies performed8. In Australia, where skin cancer is a significant 
health issue, GPs already excise the majority of skin cancers9. With the rising incidence of 
skin cancer it is likely that its management will increasingly fall into the realm of general 
practice. Therefore, it is necessary to gain insight into the quality and necessity of surgical 
approaches used by GPs at present. This study aims to describe the spectrum and quality 
of surgical procedures used by GPs in patients with skin tumours. 
Material and methods
Population 
A retrospective study on pathology reports of skin tumours excised by GPs during the 
year 2009 was performed. These specimens were investigated by the histopathology 
department of the Rijnstate Hospital in Arnhem, the Netherlands. In 2009, this region 
comprised a total of 161 GPs. We only included reports with a malignant or benign tumour 
in the (differential) diagnosis. Reports of non-tumour material (e.g. eczema, psoriasis) 
were excluded. 
Abstract 
Background 
Due to rapid increase in the incidence of skin cancer, it seems inevitable that general 
practitioners (GPs) will play a larger role in skin cancer care. 
Objectives 
To assess surgical procedures used by GPs in skin tumour management. 
Methods 
We performed a retrospective study of 1898 pathology reports of skin tumours excised 
by GPs in 2009.
Results 
In 22.9% no diagnosis was provided on the application form. Mostly, once-off excisions 
(no preceding biopsy) were performed, 7% of excised lesions were malignant, 35% of 
excisions were incomplete. Excisions in the face and neck region were incomplete in 
65.4%; 22% of melanomas were biopsied or shaved. 
Conclusion 
This study underlines the difficulties in skin tumour management in primary care. To 
stimulate adequate resource use, the number of excisions of benign lesions could be 
lowered, and pretreatment biopsy in non-melanoma skin cancer management should be 
encouraged. GPs should be aware of their limitations and consider referral of high-risk 
malignancies. 
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Table 1 provides an overview of histopathological diagnoses and lesion locations. Of all 
lesions 6.74% were malignant, 89.52% were benign, and 3.74% were pre-malignant. 
 In the present study a mean of 11.7 lesions were excised per GP over one year, 
including a total of 159 NMSCs (BCC, SCC, BD, AK and other malignant) excised by all 161 
GPs (<1 per GP); furthermore a total of 23 melanomas were excised by all GPs (1 melanoma 
for every 7 GPs).
The surgical procedures used by GPs included: 
1)  excision: wide local excision which includes excision of a lesion along with an area of 
healthy skin (used for treatment or diagnosis)
2)  punch biopsy: diagnostic procedure, performed with a small circular blade 
3)  re-excision/excision recurrence: excision of a lesion that was not excised completely 
in a previous excision, or excision of a recurrence after previous treatment
4)  shave procedure: horizontal cut with a scalpel to excise the protruding and/or in 
depth fragment of a tumour
5)  curettage: removing a protruding tumour more fragile than the rest of the skin with 
the use of a sharp ring or spoon curette
6)  excisional biopsy: performed with a circular blade (punch biopsy) to completely 
excise a lesion. 
The recorded data included the tumour location, the diagnosis of the GP written on the 
histopathology form, the final histological diagnosis, the procedure used and the 
completeness of the excision in case the lesion was (pre)malignant. 
 The histopathology form used by GPs was a standard form, containing open questions 
on tumour description and differential diagnosis. In case more than one differential 
diagnosis was provided, the first was considered to be the main clinical consideration. 
Personal data on the GPs were not available to the researchers in order to create an 
anonymous database; therefore GPs could not be contacted in case of missing data. 
Statistics
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS®) 
for Windows (version 20.0). Descriptive statistics and crosstabs were used to calculate the 
different numbers and percentages. 
Results
A total of 2527 reports concerning skin-related material provided by GPs were collected 
by the pathology department. After selection, 1898 reports were included in the study. 
Excluded reports were those of non-tumorous lesions, e.g. eczema or psoriasis. 
 The specimens comprised once-off excisions (excision without preceding biopsy) 
(58.4%), diagnostic punch biopsies (17.9%), shave procedures/curettages (22.3%), excision 
biopsies (0.3%), re-excisions (0.4%), excision following a punch biopsy (0.1%) and excision 
of a recurrence (0.1%). In 0.5% the type of procedure was unknown. 
Table 1   Overview of lesion location and histopathological diagnosis of all material 
collected by GPs.
n %
Histopathological diagnosis
Malignant
     Basal cell carcinoma 88 4.6%
     Squamous cell carcinoma 16 0.8%
     Melanoma 23 1.2%
     Other malignant* 1 0.1%
Premalignant
     Bowen’s disease 12 0.6%
     Dysplastic naevus 17 0.9%
     Actinic keratosis 42 2.2%
Benign
     Seborrhoeic keratosis 518 27.3%
     Keratoacanthoma 46 2.4%
     Naevus 881 46.4%
     Lentigo simplex 2 0.1%
     Dermatofibroma 188 9.9%
     Fibroma 33 1.7%
     Other benign 31 1.8%
Location of lesion
Head and neck 427 22.5%
Trunk 878 46.3%
Extremities 523 27.5%
Unknown 70 3.7%
Total 1898
* Metastatic breast cancer
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Completeness of excisions 
The completeness of excisions was only assessed in (pre)malignant lesions, since in these 
lesions this is of clinical relevance; only once-off excisions were included. An overview of 
the completeness of excisions is shown in table 4. A total of 17 melanomas were excised, 
including 3 in situ melanomas (one of these included the one with ‘unknown 
completeness’), 7 melanomas with a Breslow < 1 and 6 melanomas with a Breslow > 1 
(including one ‘not completely excised’). The thickness of one melanoma was unknown. 
Of (pre)malignant lesions located in the face and neck region 65.4% were incompletely 
excised, as compared to 29.5% on the trunk and 10.7% on the extremities. 
Histopathology form use
In 22.9% (434/1898) GPs did not add any diagnosis to the histopathology form; of these 
lesions 21.2% (92/434) were (pre)malignant on histology. In 25.0% (32/128) in the subgroup 
of histologically diagnosed malignant lesions, GPs also considered a malignancy, whereas 
72.9% (1239/1699) of benign lesions were considered as benign. In 8.5% (6/71) in the sub- 
group of histologically diagnosed premalignant lesions were considered premalignant. 
The accuracy of defining (pre)malignancies by GPs corresponds with a sensitivity of 25.1% 
(50/199) and specificity of 72.9% (1239/1699) when all samples are counted. When excluding 
application forms without a clinical consideration, the sensitivity rises to 42.7% (50/117) 
and the specificity to 92.0% (1239/1347). The GPs identified 21.6% (19/88) of BCCs, 0% 
(0/16) of SCCs, and 8.7% (2/23) of melanomas on their histopathology form. In case of 
SCC, the consideration of BCC was mentioned in 56.3% (9/16). 
Type of surgical procedure
In 7.1% (79/1108) of all once-off excisions performed by GPs, histological results reported 
a malignancy, whereas in 6.5% (22/340) of the punch biopsies a malignancy was 
demonstrated. The surgical procedures used by GPs in case of (pre)malignancy, are 
shown in table 2 (based on the differential diagnoses of GPs) and table 3 (based on the 
final diagnoses of the pathologists). Of lesions excised under consideration of BCC, 22.4% 
appeared to be a BCC.
Table 2   Procedures used when general practitioners (GP) considered a malignant or 
premalignant lesion (absolute numbers).
GP’s consideration Excision Punch 
biopsy
Re-excision/ 
excision 
recurrence
Shave Excisional 
biopsy
Unknown Total
Basal cell carcinoma 51 25 1 12 2 3 94
Squamous cell 
carcinoma
2 2 - 1 - - 5
Melanoma 10 - 1 1 - - 12
Bowen’s disease 3 1 - - - 1 5
Dysplastic nevus 20 8 - 3 - - 31
Actinic keratosis 2 4 - 3 - - 9
Table 3   Procedures used by general practitioners in case of (pre)malignant 
histopathologic results (absolute numbers).
Histopathological 
diagnosis
Excision Punch 
biopsy
Re-excision/
excision 
recurrence
Shave Excisional 
biopsy
Unknown Total
Basal cell carcinoma 49 16 3 17 - 3 88
Squamous cell 
carcinoma
13 1 - - 2 - 16
Melanoma 17 4 1 1 - - 23
Bowen’s disease 4 4 1 2 1 - 12
Dysplastic nevus 17 - - - - - 17
Actinic keratosis 8 15 - 19 - - 42
Table 4   Completeness of excisions in case of (pre)malignant histopathologic 
diagnosis. n(%)
Incomplete Complete Doubtful/
unknown
Total
Basal cell carcinoma 25 (51.0%) 22 (44.9% )  2 (4.1%) 49
Squamous cell carcinoma  5 (38.5%)  8 (61.5%)  0 (0.0%) 13
Melanoma  1 (5.9%)  15 (88.2%)  1 (5.9%) 17
Bowen’s disease  1 (25.0%) 3 (75.0%) 0 (0.0%) 4
Dysplastic nevus  3 (17.6%)  10 (58.8%)  4 (23.5%) 17
Total  35 (35.0%)  58 (58.0%) 7 (7.0%) 100
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may be less expensive. Furthermore, a pathological diagnosis obtained through biopsy is 
of value in the treatment choice, since the diagnosis determines the margins used in 
excision. Additionally, in case of a superficial lesion (AK, BD, superficial BCC), a non-invasive 
treatment may be preferred. In this case a diagnostic biopsy could also prevent an 
unnecessary excision. However GPs should be aware of the fact that there are mixed type 
BCCs and that there may be a sampling error when performing a biopsy13.
 If GPs considered SCC or AK as a diagnosis, the number of excisions performed was 
almost equal or lower to the number of other types of procedures chosen (e.g. biopsy). 
Since AK can usually be diagnosed clinically and non-invasive treatment is advised, it is 
encouraging to notice that less extensive procedures are used in the diagnosis of AK. 
 In almost all patients in whom GPs considered a melanoma, a diagnostic excision was 
performed. However, in case of clinical suspicion of a dysplastic naevus (with melanoma 
as an important differential diagnosis), GPs performed a biopsy or shave procedure in 11 
(35.5%) patients. According to the Dutch and British melanoma guidelines it is advised to 
perform a diagnostic excision with a 2-mm margin in case of suspicion for melanoma14,15. 
Furthermore, both guidelines advice GPs to refer patients with lesions suspicious for 
melanoma14,15. Therefore, the question arises whether all GPs in our study were sufficiently 
aware of the directives provided by guidelines for skin cancer. Furthermore it was found 
that the number of in situ melanomas excised was small in this study. This might indicate 
that these were not detected by GPs, or they might have been referred to dermatologists. 
Surgical procedures in pathologically proven (pre)malignancies
While 92% of lesions suspected of being melanoma were managed by excision only 74% 
of pathologically diagnosed melanomas were managed this way, the remainder being 
managed by biopsy or shave.This may indicate that GPs are aware of the fact that when a 
melanoma is suspected, apart from referral, no less than an excision is needed. However, 
the recognition of a melanoma appears to be more difficult. In case of a shave procedure 
of a melanoma, the GP was mostly in the assumption of treating a benign nevus. 
A dermatoscope may be a useful tool to help the GP differentiate between melanomas 
and benign lesions, however adequate experience is necessary16,17. 
Completeness of excisions
The highest percentage of complete excisions was observed in the group of melanomas. 
Bakhai et al.18 found a complete excision rate of 83.8% in melanomas excised by 
consultants as compared to 62.3% in those excised by GPs in the UK. Consultants’ excision 
margins were compliant with the guideline in 70.5%, those of GPs in 29.8%. According to 
the guidelines, diagnostic excision of a melanoma is performed with a 2 mm margin14,15. 
Since not all GPs may be aware of this directive, this may lead to the use of a wider margin 
and therefore a higher number of complete excisions. It should be noted that the number 
of melanomas excised by GPs in this study is small. 
Discussion
The present study provides insight into surgical procedures performed by GPs in the 
management of skin tumours. The chosen procedure types were related to GPs’ differential 
diagnosis and the pathological outcome. 
 A potential limitation of our study may be that findings are based on a retrospective 
study in a regional population, and that the numbers in some individual tumour groups 
are low. Data analysis was only performed on a group level, not on an individual level. 
Therefore it should be stressed that our results represent the average diagnostic and 
surgery skills of this group of GPs; individual practitioners may have far better (or worse) 
results. Additionally, it should be noted that GPs may provide samples for histological 
evaluation to exclude a malignancy (rather than to confirm a diagnosis), which might 
influence the choice of diagnosis on the histopathology form. However, the present 
study does reflect real life practice in primary care with respect to the surgical procedures 
used in patients with skin tumours.
Histopathology form use 
In 22.9% of cases GPs did not propose a diagnosis on their histopathology form; therefore 
it remains unclear which consideration the GP had that led to the procedure. Delaney 
et al.10 also noted that most histopathology forms of GPs and hospital specialists did 
not include a presumptive diagnosis. It may be concluded that many physicians are not 
aware of the fact that a diagnosis/consideration on the histopathology form may be of 
help for the pathologist in establishing the diagnosis. 
Incidence and management of benign lesions
The majority of excised skin lesions in this study was diagnosed as benign. In a study 
performed by Buis et al.11 high numbers of benign lesions were submitted for pathological 
evaluation by GPs as well, with only 4.7% being (pre)malignant. The higher percentage of 
(pre)malignancies observed in the present study may be due to the increase in skin 
cancer incidence in the last 10 years, or may reflect regional differences. 
 Most benign lesions in the present study were also clinically considered to be 
benign. The intentional excision of a benign lesion may be due to the patient’s request12 
or to diagnostic doubt of the GP. However, in many cases a less invasive method, e.g. a 
shave procedure or curettage, may have been more appropriate.  
Surgical procedures in clinically suspected (pre)malignancies
In the case of suspicion on SCC or AK, biopsy procedures were more likely than excisions. 
Of lesions excised under suspicion of BCC, this diagnosis was only correct in 22.4%. 
Therefore, in case of diagnostic doubt a punch biopsy would be preferred above once-off 
excision, since a biopsy is less invasive (more patient-friendly), less time consuming and 
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In NMSC, diagnostic difficulties could contribute to incomplete once-off excisions. 
Moreover, demarcation of the border of these tumours may be difficult in some cases. 
Due to the retrospective study design, specific tumour characteristics, surgical experience 
of GPs and excision margins could not be taken into account. Therefore, we are not able 
to draw conclusions on margins used in excision, only on the completeness of the 
excisions.
 With respect to tumour location, tumours excised in the head and neck region had 
the highest percentage of incompleteness, but also excisions of malignancies on the 
trunk or extremities were often incomplete. In previous studies it was also reported that 
in the head and neck region more incomplete excisions were performed8,19. To lower 
the number of unnecessary excisions and re-excisions, GPs are advised to perform a 
representative biopsy of suspicious non-melanoma tumours. If thereafter excision is 
needed, the GP should preferably refer to a hospital specialist (e.g. dermatologist). BCCs in 
the head and neck area with poorly defined borders, which are considered high-risk 
BCCs20, require wider surgical margins and these patients should preferably be referred to 
a hospital specialist (e.g. dermatologist). Furthermore, in areas in which the incidence of 
skin cancer is much higher as compared to Western Europe, GPs are often capable of and 
used to perform excisions of these tumour types themselves. However, our data show 
that in countries in which skin cancer training is limited, GPs often have difficulties in 
excising high-risk skin cancers in the face.
Implications for practice 
GPs’ capacity in the diagnosis and treatment of skin tumours could be improved. The 
following might be essential in the training of GPs:
1)  With respect to benign lesions, GPs may consider whether excision is necessary. 
2)  In NMSC, where the diagnosis of the specific tumor (sub)type is in doubt, a preliminary 
biopsy is the diagnostic method of choice because the pathological results may prevent 
an excision which may be unnecessary or performed with wrong margins in case of 
misdiagnosis. The performance of a diagnostic biopsy also provides feedback for 
GPs on their differential diagnosis and may be of educational value. 
3)  To provide insight into appropriate margins for the individual tumour types, guideline 
use should be encouraged .  
4) In melanocytic lesions a diagnostic excision should be performed, however in case 
of suspicion of a melanoma, patients should also be treated as stated in guidelines; in 
most countries this means referral to a dermatologist. 
5)  GPs are also advised to be aware of their limitations and consider referral of (high-risk) 
BCCs (depending on their clinical experience) as well as SCCs (for their metastatic 
potential) to a dermatologist.
6)  Finally, to support the pathologist, it is advised to add a clinical consideration to the 
histopathology form for pathological investigation. 
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Introduction
Basal cell carcinoma (BCC) is the most frequently diagnosed cancer in Caucasians, with a 
rapid increasing incidence1. As a consequence, the financial burden for our healthcare 
system will expand further1. Therefore, it is relevant to critically evaluate diagnostic and 
treatment protocols. 
 BCCs represent the largest group of non-melanoma skin cancer (NMSC). Although 
they have a low metastatic potential, treatment is necessary to prevent (further) invasion 
and destruction of the skin and underlying tissues. Topical and surgical treatments are 
available, however surgical excision is performed in the majority of cases2,3. Generally, 
prior to excision, a diagnostic biopsy is performed to verify the diagnosis and to identify 
the BCC’s histological subtype. Treatment choice and surgical margins are based on the 
most aggressive subtype. However, the accuracy of a diagnostic biopsy for BCCs is limited 
and the most aggressive subtype may be missed4,5. Furthermore, international guidelines 
are not uniform in the urge for a biopsy prior to treatment6-8. While, the Dutch guideline 
recommends to perform a diagnostic biopsy prior to treatment choice9, many 
dermatologists perform once-off excisions (without previous biopsy) of lesions that are 
clinically suspected for BCC.
 Since punch biopsies and their pathological examination are costly and time-
consuming, the question rises whether it is more efficient to excise all clinically suspected 
lesions by once-off excision. The aim of this study was to compare once-off excised BCCs 
with BCCs excised after biopsy, with respect to completeness and efficiency.
Materials and method
A retrospective study was performed on specimens processed by the pathology 
department of the Rijnstate hospital in Arnhem, the Netherlands, over the year 2009. 
Selected specimens comprised only those provided by dermatologists. In 2009, seven 
dermatologists were working at the Rijnstate hospital, their working experience as a 
dermatologist ranged between one to 27 years. 
 Specimens investigated met the following inclusion criteria: differential diagnosis 
and/or histological diagnosis of BCC, and treatment by a once-off excision or excision 
after diagnostic biopsy. Punch biopsies, excisions of recurrences, or re-excisions were 
excluded.  
 The following data were obtained from the included reports: differential diagnosis 
(the first mentioned), histological diagnosis, BCC subtype, location of the tumour, 
completeness of the excision, excision type, and the occurrence of a recurrence.
Abstract 
Background
Basal cell carcinoma (BCC) is the most occurring cancer in Caucasians. Many BCCs are 
diagnosed by punch biopsy, however, these are costly and time-consuming. Therefore, 
the question rises whether once-off excision (without previous biopsy) is more efficient.
Objectives
To compare once-off excised BCCs with BCCs excised after biopsy, with respect to 
completeness and efficiency.
Methods
A retrospective study was performed on pathology specimens from 2009, of lesions with 
a differential- and/or histological diagnosis of BCC. Completeness was analysed in 
histologically proven BCCs. Efficiency was defined as time spent on biopsy and/or 
excision in lesions suspicious for BCC. Two-way sensitivity analysis was performed to 
prove the most time-efficient strategy. 
Results
In total 844 once-off excisions and 357 excisions after biopsy were included. In once-off 
excisions the diagnosis BCC was correct in 84.2%. Overall, no significant difference in 
completeness between excision types was found. For nodular BCCs, excision after biopsy 
was significantly more often complete. In biopsies taken prior to excision of infiltrative 
BCCs, significantly more sampling errors were present in the ‘incomplete excision group’. 
Based on sensitivity analysis, with a mean excision time of 13 minutes, once-off excision 
was found more efficient if biopsy takes >1.94 minutes.
Conclusion
Diagnostic biopsy in nodular BCC may contribute to completeness of excision, however, 
overall (all BCC types) no significant difference in completeness was found. Furthermore, 
sampling errors in biopsies of mixed type BCCs, may affect the excisions’ completeness. 
However, to be more conclusive in omitting diagnostic biopsies, prospective research is 
essential.
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Results
A total of 1201 specimens remained after selection, including 357 excisions after biopsy 
and 844 once-off excisions. Six hundred eighty-one lesions were located in the head and 
neck region, 360 on the trunk, and 150 on the extremities. Of 10 lesions, the location was 
unknown. A total of 1073 (89.3%) of all lesions appeared to be BCCs, of which 151 were 
superficial, 805 nodular, 107 infiltrative, nine basosquamous, and of one lesion the subtype 
was unknown. 
 The group of once-off excised lesions comprised 716 (84.8%) BCCs, 13 (1.6%) squamous 
cell carcinomas, 5 (0.6%) melanomas, 3 (0.4%) dysplastic naevi, 15 (1.8%) Bowen’s disease, 
29 (3.6%) actinic keratoses, and 63 (7.8%) benign lesions.
 In 812 of all once-off excised lesions, the differential diagnosis of a BCC was mentioned. 
Within these 812 lesions the diagnosis BCC was histologically confirmed in 84.2%. Out of a 
random sample of 149 diagnostic biopsies performed in 2009 under suspicion of a BCC, 
the diagnosis BCC was histologically confirmed in 123 (82.6%) lesions.  
Completeness of excisions 
In total 11.4% of all BCCs were incompletely excised. BCCs located in the face/neck region 
(table 1) and the ones with an infiltrative subtype were significantly more often 
incompletely excised (P < .001). 
Superficial BCCs were more often located on the trunk (61.3%), while nodular and 
infiltrative BCCs were more often located in the face and neck region (resp. 62.7% and 
78.3%). BCC subtypes were equally divided between the two excision groups (P = 0.501). 
Overall, we found no significant difference in completeness between BCCs excised 
following a biopsy or once-off excised BCCs (resp. 9.5% and 12.3%, P = 0 .179). 
 By performing an analysis per BCC subtype, a difference in completeness between 
excision types was found for nodular BCCs. In nodular BCCs, excision after biopsy was 
significantly more often complete (table 2). In superficial and infiltrative BCC, no significant 
differences were found between excision types (table 2). 
Completeness of excision 
Completeness of the excision was defined by the pathologist. An excision was complete 
in case no tumour was involved in surgical margins. An additional analysis took place of 
all BCCs diagnosed with an infiltrative subtype after excision. Of these BCCs the diagnostic 
punch biopsies performed prior to excision were also collected and analysed.
Efficiency of excision
The level of efficiency was defined as the time the dermatologist had spent on 
performing a biopsy and/or excision. Time spent on patients who had a once-off excised 
lesion was compared to time spent on those who underwent a biopsy prior to excision. 
To define dermatologists’ diagnostic accuracy in diagnosing a BCC prior to biopsy, a 
sample selection was carried out in patients with lesions suspicious for BCC who were 
biopsied in 2009.    
 To estimate the mean excision time, dermatologists working at the Rijnstate hospital 
collected data on the duration of 40 excisions of skin tumours on the body, face, or neck 
region. It should be noted that although patients and materials were often prepared by a 
nurse, the nurse’s time was not included in our analysis. 
Data analysis
Statistic analysis was performed using the Statistical Package for Social Sciences (SPSS®) 
for Windows (version 20.0). Descriptive statistics and crosstabs were used to calculate 
percentages. All bivariate relations were studied in crosstabs with a Chi-square test or a 
Fisher exact test (in case of low expected numbers). To correct for possible confounding 
and to be able to detect interaction between excision type and BCC subtype, logistic 
regression was performed, with completeness of excision as dependent variable. The 
relations as found in the logistic regression model were comparable with the crude 
relation (no confounding). Therefore, only cross tables are presented. A p-value of <0.05 
was considered significant.
 TreeAge Pro 2014 was used for a decision model, to compare time spend on a 
once-off excision to the time spend on a biopsy followed by excision in patients 
suspected of BCC. Since excision time and biopsy time may vary per lesion a two way 
sensitivity analysis was performed to provide insight in the most time-efficient strategy, 
dependent on the values of these two parameters. 
Table 1   Completeness of all excisions based on location. (n(%))
Location Incomplete Complete Total P-value
Face and neck 97 (15.9%) 514 (84.1%) 611 (100%)
Trunk 21 (6.5%) 304 (93.5%) 325 (100%)
Extremities 3 (2.3%) 125 (97.7%) 128 (100%) .000
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When examining the influence of the body location on the completeness of the excision 
no significant differences were found between the two excision groups, (face and neck 
region P = 0.473, trunk P = 0.081, extremities P = 1.000). 
 During follow up, recurrences occurred in 9 (1.5%) patients with a once-off excised 
BCC and in 6 (2%) patients with excision after biopsy. There was no significant difference 
between these groups (P = .586).
Efficiency of excisions 
Out of 40 excisions performed by dermatologists, a mean excision time of 13 minutes 
(range 5-22, SD 3.9) was calculated. A model was performed using a chance of 84.2% on a 
BCC after once-off excision or biopsy in case of suspicion on a BCC (figure 1). This 
percentage was chosen since it was based on the highest number of reports and was 
almost equal to the percentage of correctly diagnosed BCCs prior to biopsy. Based on this 
model, with a mean excision time of 13 minutes, it appears to be more time efficient to 
perform a once-off excision in case it would take more than 1.94 minutes to perform a 
biopsy (figure 2). Analysis of the diagnostic biopsies taken prior to excision of infiltrative BCCs, showed that 
the diagnosis of an infiltrative BCC was significantly more often missed (sampling error) 
in the ‘incomplete excision group’ (table 3). In patients in the ‘incomplete excision 
group’, the biopsy only mentioned  a nodular or superficial BCC in eight patients (61.5%). 
In patients with a completely excised BCC, a nodular BCC was found in 4 (23.5%) of 
the biopsies performed prior to excision.
Table 2   Comparison of completeness of once-off excisions as compared to excisions 
after biopsy per basal cell carcinoma (BCC) subtype. (n(%))
BCC subtype Incomplete Complete Total P-value 
Superficial Once-off excision 7 (7.3%) 89 (92.7%) 96 (100%)
.748Excision after biopsy 3 (5.5%) 52 (94.5%) 55 (100%)
Nodular Once-off excision 59 (11.0%) 476 (89.0%) 535 (100%)
.047Excision after biopsy 18 (6.7%) 252 (93.3%) 269 (100%)
Infiltrative Once-off excision 22 (28.6%) 55 (71.4%) 77 (100%)
.144Excision after biopsy 13 (43.3%) 17 (56.7%) 32 (100%)
Baso-
sqamous 
Once-off excision - 7 (100.0%) 7 (100%)
-Excision after biopsy - 2 (100.0%) 2 (100%)
Table 3   Pathologic results of diagnostic biopsies as compared to the results after 
excision within the group of infiltrative basal cell carcinomas (iBCC)
Biopsy nodular/
superficial
Biopsy infiltrative Total P-value 
Incomplete excised iBCC 8 (61.5%) 5 (38.5%) 13 (100%)
.035Complete excised iBCC 4 (23.5%) 13 (76.5%) 17 (100%) Figure 1  Tree age model to compare the strategies ‘Biopsy’ (in case of BCC followed 
by excision) and ‘Once-off excision’. Chance on a BCC equals 0.842 (P_malignant), mean 
biopsy time equals 4 minutes (Time_Biopsy) and mean excision time equals 13 minutes 
(Time_Excision). Outcome measure is the mean time used to treat a patient in a given 
strategy.
Biopsy
Once-off excision
BCC
P_malignant
P_malignant = 0.842
Time_Biopsy = 4
Time_Excision = 13
Patients suspect 
for BCC #
#
P_malignant
No BCC
BCC
No BCC
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 In the group of infiltrative BCCs, no significant difference with respect to the 
completeness of excisions was found. This is surprising, since the surgical margin used for 
an infiltrative BCC needs to be wider than the margin used for the other subtypes. An 
explanation for this finding could be the fact that in the incompletely excised infiltrative 
BCCs, in 61.5% of the biopsies prior to excision, different BCC subtypes (superficial and 
nodular) were found, leading to smaller margins during excision. Betti et al. also found 
that margin involvement was more frequent in mixed type BCCs11. 
With respect to efficiency, it was found that based on a mean excision time of 13 minutes, 
a once-off excision would be more efficient if the time to perform a biopsy would be 
more than 1.94 minutes. This is a very short time frame, therefore it may be considered to 
chose for biopsy only in case more time is needed for an excision. 
 What should be considered is that in some hospital settings biopsies are performed 
by nurses, which saves doctors time. Also, from patient’s perspective, it would be more 
convenient to perform a biopsy instead of an excision that could have been prevented. 
Furthermore, the performance of a biopsy could differentiate between different types of 
malignancies in case of diagnostic doubt and contribute to the urgency of the excision. 
In case of a superficial BCC a non-invasive treatment could be used. However, as 
compared to once-off excision, a biopsy costs time to perform, time to inform the patient, 
and extra costs are spent on materials and pathology analyses. Furthermore, it may delay 
the time to the actual excision. 
Since this study was retrospective, it was not clear what made the dermatologist decide 
to perform a biopsy or a once-off excision, tumour characteristics and excision margins 
were unknown. To make recommendations on omitting incisional punch biopsies in 
specific cases, further prospective research has to be performed. 
Conclusion
As far as we know, this is the first study to investigate the efficiency of diagnostic biopsies 
and the effect of these biopsies on completeness of excisions in BCC. It was found that 
performance of a diagnostic biopsy in nodular BCC may contribute to the completeness 
of the excision, however in general a biopsy does not influence the chance on surgical 
completeness. On the other hand sampling errors in biopsies may mislead the 
dermatologist in treatment and margin selection. A prospective study to investigate 
tumour characteristics, excision margins and reasons to chose for an incision biopsy or a 
once-off excision, may contribute to an evidence based differentiation of cases in which a 
diagnostic biopsy may be indicated. 
Discussion
Overall, we found no significant difference in completeness of excisions between excision 
after biopsy and once-off excision. In a subgroup analysis per BCC subtype, only a 
significant difference in completeness of the excisions in the group of nodular BCCs was 
found. In this subgroup once-off excision led to more incomplete excisions. This is 
surprising since the margin for excision of a nodular BCC according to the Dutch guideline 
is 3 mm9 (unless the tumour is > 1 cm), which is the smallest margin advised in BCC. An 
explanation for this difference might be that only biopsies were performed in those BCCs 
in which other factors may have had an influence on completeness, e.g. tumours on high 
risk sites, that are poorly defined, or have a larger diameter7. As a consequence, these 
tumours may have been excised with greater caution than the nodular BCCs that were 
not biopsied. The nodular BCCs that were not biopsied may have been smaller, more 
straightforward, and easier to excise. Therefore, smaller margins than 3 mm could have 
been used. In a study performed by Borgonjen et al.10 it was found that only 63% of 
dermatologists use excision margins for low risk BCC (3 mm) as mentioned in the 
guideline.
Figure 2  Result of a two way sensitivity analysis with ‘Excision time’ and ‘Biopsy time’ as 
independent variables. A point in the red plane denotes a combination of ‘Excision time’ 
and ‘Biopsy time’ for which the strategy ‘Once-off excision’ is the most time efficient. 
A point in the blue plane denotes excision with a previous biopsy as most time efficient. 
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Introduction
Actinic keratoses (AKs) are chronically recurrent premalignant lesions that occur mainly 
on chronically sun-exposed skin in Caucasians. In a recent study conducted in the 
Netherlands, a prevalence of AKs of 49% in men and 28% in women was found in a 
cohort of the general population aged 45 years or above1. Studies performed in other 
countries also show that AK frequently occurs in the elderly population2,3. Because of the 
potential of AK to develop into squamous cell carcinoma (SCC), treatment is 
recommended. Given the high incidence of AKs and their predominant occurrence in the 
head and neck region, a cost-effective therapy with good cosmetic results is needed. 
Treatment can be directed at individual lesions, and cryotherapy is the most common 
treatment used. For patients with multiple AKs and in field cancerization, a field-directed 
approach is considered more appropriate, e.g. photodynamic therapy (PDT), imiquimod 
cream (IMI) or 5-fluorouracil cream (5-FU)4. Within the group of field-directed treatments 
no specific patient characteristics to guide treatment choice have been defined. 
Although personalized medicine and costs are nowadays of great importance in 
treatment choice, only a few studies on the cost of field-directed treatments have been 
published5-7. Most of these studies are based on the results of randomized controlled 
trials (RCTs), in which selected patients with few AKs are treated and treatment choice is 
based on randomization. It is also known that patients in RCTs do not provide an 
adequate reflection of real-life clinical practice8. The present study aimed to investigate 
whether patient characteristics play a directive in treatment choice in methylaminolae-
vulinate (MAL)-PDT, IMI and 5-FU in real-life practice in patients with AKs on the face and/
or scalp. Furthermore, data on the cost and effectiveness of these treatment modalities 
were collected. 
Materials and methods
Study design
Multicentre, 1-year observational study, conducted in 2 general and 2 university hospitals 
in the Netherlands. 
Patients
Patients of 18 years and older, with a clinical diagnosis of AKs on the face and/or scalp 
region, suitable for field-directed treatment (AK in close proximity from each other), were 
included in the period October 2009 to June 2011. Patients were excluded in case of 
pregnancy, breast-feeding or contra-indications to field therapy. The study was approved 
Abstract 
Actinic keratoses (AK) occur frequently; however, real-life clinical data on personalized 
treatment choice and costs are scarce. This multicentre one-year observational study 
investigated patient-characteristics, cost and effectiveness of methylaminolaevulinate 
photodynamic therapy (MAL-PDT), imiquimod (IMI), and 5-fluorouracil (5-FU) in patients 
with AKs on the face/scalp. A total of 104 patients preferred MAL-PDT, 106 preferred IMI 
and 110 preferred 5-FU. At baseline, significant differences between treatment groups 
were found; most patients were severely affected (mean 32.5 AK in PDT-group, 20.2 in 
IMI-group, 22.8 in 5-FU-group). A mean reduction in lesions of 81% after MAL-PDT, 82% 
after IMI, and 88% after 5-FU was found after one year. Annual costs were €1,950 for 
MAL-PDT, €877 for IMI and €738 for 5-FU. 
 These results show that, compared with clinical trials, in the real-life clinical setting 
AK patients are usually more severely affected and treatment costs are much higher. 
Furthermore, patient characteristics are important factors in treatment choice.
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scheduled at 3 months (M3) and at 12 months (M12) after treatment start. If necessary, 
extra appointments were made at the outpatient clinic (e.g. in case of subsequent 
treatment). Patients treated with IMI were also seen at 8 weeks after treatment start to 
evaluate the effect of the treatment. Effectiveness of the treatment for study purpose was 
evaluated only at M3 and M12. 
 At baseline, the following data were collected: age, sex, race and Fitzpatrick skin type 
of the patient; location, number and severity of AKs (according to the Olsen classification), 
number of diagnostic biopsies, previous AK treatments, patients’ medical history and 
medication use. Presence of hypopigmentation, hyperpigmentation, atrophy, erythema, 
induration, scar formation, hyperkeratosis, and desquamation of the treatment area were 
scored.
Outcomes
Subjects were evaluated at M3 and M12. The following information was recorded: 
Effectiveness of treatment
-  Lesion response: the total number of AKs was evaluated by inspection, palpation and 
photography of the treatment area. Lesion response was registered as complete in 
case of 100% clearance. 
-  Cosmetic results: cosmetic score was classified as excellent when there was no scarring, 
atrophy, or induration and no or slight occurrence of erythema or change in 
pigmentation. 
Consumption of care and associated costs. All costs related to the treatment of AK in the 
face/scalp during one year were collected. Total costs were calculated by multiplying 
every item with the unit costs. Standard unit costs as established by the National 
Healthcare Insurance Board of the Netherlands were used where possible, otherwise 
costs were gathered from the hospital administration, and converted to the 2011 price 
level9. Where relevant, different costs were used for general hospitals and university 
hospitals (general hospital €66 for a consultation, university hospital €134)10. MAL-PDT 
costs were based on the costs for day-care admission (€251)10, costs for grams of MAL 
used (tube 2 gram €272, weighed before and after treatment), standard materials used 
(e.g. occlusive dressing, light source), and the costs for personnel. IMI was prescribed per 
treatment cycle, including 12 sachets (€60). For 5-FU one tube for the whole treatment 
area could be used (€41). The cost of a diagnostic biopsy was €150, including costs for 
pathologic evaluation. 
 Mean costs per patient were calculated over a one-year period for each treatment 
group. In addition, mean costs per individual AK lesion were calculated. 
by the local ethics committee of all participating institutions. All patients gave written 
consent to participate in the study. 
Treatment modalities
Treatment choice between MAL-PDT, IMI and 5-FU was based on patients’ preference 
(after explanation on the treatment options) in combination with the clinical appearance 
of AKs. The use of treatment was standardized in the participating hospitals.   
PDT. During one week prior to PDT, patients were pre-treated with a keratolytic ointment 
(10% salicylic acid in petrolatum) to remove hyperkeratosis. On the PDT day (at the 
day-care centre), remaining hyperkeratoses were carefully removed by curettage and the 
skin was wiped with alcohol. In addition, a thin layer (approximately 1 mm) MAL cream 
(Metvix®; Galderma) was applied on the treatment area, and covered with an occlusive 
dressing and tinfoil to prevent influence of light. After 3 hours the dressing and cream 
were removed and the skin was illuminated with a red light (632 nm, 37J/cm2) from a 
light-emitting diode light source (Aktilite®). Three months after PDT, clearance of AKs was 
assessed. In case of remaining AKs, additional treatment could be performed. 
Imiquimod. IMI (Aldara®, MEDA) was used at home 3 times per week (Monday, Wednesday 
and Friday) for 4 consecutive weeks. Cream was applied prior to normal sleeping hours, 
and removed in the morning, after approximately 8 hours. Sufficient cream was applied 
to cover the treatment area (never more than 1 sachet). In case of an intense local 
reaction, treatment was interrupted and continued after recovery. Four weeks after 
finishing treatment, clearance of AKs was assessed. In case of remaining AKs, additional 
treatment could be performed.
5-FU cream. A sufficient amount of 5-FU cream was applied at home, twice daily, to cover 
the treatment area, until erosions, redness and crusting occurred (duration 2 - 4 weeks). 
After 3 months, in case of remaining AKs, additional treatment could be performed.
Subsequent and concomitant treatment. In case of AKs remaining after finishing the initial 
treatment of choice, patients received subsequent treatment, which could be a treatment 
other than the initial treatment. Depending on the number of AKs and the patient’s 
preference, this could be lesion-directed (cryotherapy) or field-directed therapy. In case 
side-effects occurred (e.g. itching, infections) patients received concomitant treatment, 
e.g. topical corticosteroids or antibiotics. 
Design
All patients were included and followed by the same 2 investigators. Patients were 
included at baseline (M0), prior to the start of the treatment. Follow-up evaluation was 
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Analysis
Study size determination. A sample size calculation was performed in order to obtain a 
sufficiently precise estimate of the proportion of patients in remission at 1-year follow-up. 
This was based on the following assumptions: an overall remission percentage of 70% 
(86% for IMI, 57% for 5-FU, and 88-89% for PDT) 11,12 and a 2-sided 95% confidence interval 
with a maximum of 60-80%. This resulted in a sample size of 81 patients (α= 0.05) per 
treatment group. To control for possible loss to follow-up (LTFU), a minimum of 100 
patients per treatment group was included.
Statistical methods. Data were collected in a web application (Trial Registry Information 
and Administration System). For further analysis, data were entered into Statistical 
Package for Social Science (SPSS 20.0, IBM Corp, Armonk, NY, USA). Descriptive statistics 
and crosstabs (χ2, Fisher’s exact test) were performed to analyse the differences between 
the study groups at baseline. p-values <0.05 were considered statistically significant in 
the comparison between baseline characteristics. Based on the observational design of 
the study, and the fact that our goal was to describe real-life data rather than comparing 
effectiveness between groups, follow-up results were only described per treatment 
group. All patients were analysed according to the intention-to-treat (ITT) principle. 
Results
Study population
As this study had an observational design, most patients with field AK were willing to 
participate, thus the out-patient clinic population was well represented. Treatment choice 
was based on the patient’s preference and the clinical appearance of the AK; no 
randomization was performed. A total of 320 patients was included in the study: 104 
patients were initially treated with MAL-PDT, 106 with IMI, and 110 with 5-FU (figure 1). 
In one of the general hospitals no PDT was performed. 
 Five patients withdrew from the study directly after inclusion. Ninety-three patients 
who were treated with MAL-PDT, 101 patients who were treated with IMI, and 98 who 
were treated with 5-FU attended the M3 visit (figure 1). At M12, 17 more patients were 
LTFU (PDT 3, IMI 5 and 5-FU 9 patients). 
 As may be expected in case of a naturalistic study, statistically significant differences 
were found between the baseline characteristics of the treatment groups (table 1). 
Patients treated with MAL-PDT had significantly more AKs, a larger affected area (face in 
addition to scalp), and more previous AK treatments. Those treated with IMI were the 
youngest and had the lowest number of AKs. Patients treated with 5-FU had the worst 
baseline cosmetic scores. 
Figure 1  Included patients, patients lost-to follow-up (LTFU) prior to (no treatment) and 
after treatment (LTFU), and those who missed a visit (absent) at M3 (3 months after 
treatment) and M12 (12 months after treatment). 
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ImiquimodMAL-PDT 5-FU cream
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M3
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Absent 3
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Unknown 2
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Cosmetic results
At M12, 65.6% of patients treated with MAL-PDT, 64.9% of patients treated with IMI, and 
54.9% of patients treated with 5-FU had an excellent cosmetic outcome. 
Consumption of care and costs
An overview of subsequent treatments is shown in table 3. Patients initially treated with 
MAL-PDT had the highest number of subsequent treatments. In only a few patients was 
a second cycle with PDT or IMI, as prescribed in the treatment protocol, performed. 
Since most often only a few isolated AK lesions remained, patients were almost always 
subsequently treated with cryotherapy. Two patients (MAL-PDT and IMI group) were 
subsequently treated with CO2 laser (not mentioned in the table). 
 An overview of treatment costs per patient is shown in table 4. The mean cost per 
individual AK lesion was €87 (range €9.9 - 698.3) for MAL-PDT, €71 (range €16.0 – 527.5) for 
IMI and €55 (range €11.2-380.0) for treatment with 5-FU.
Lesion response
The mean percentage of lesion reduction, absolute number of lesion reduction, and total 
number of full responders after 3 months (M3) and 12 months (M12) are shown in table 2. 
Patients treated with MAL-PDT showed the highest absolute number of lesion reduction. 
Patients treated with 5-FU demonstrated the highest percentage of lesion reduction and 
the highest number of full responders at both M3 and M12. 
Table 1   Baseline characteristics of patients treated with methylaminolaevulinate 
photodynamic therapy (MAL-PDT), imiquimod cream (IMI), and 5-fluorouracil 
cream (5-FU) (n(%))
MAL-PDT 
(n=104)
IMI 
(n=106)
5-FU  
(n=110)
p-value 
Sex (male) 74 (71.2%) 72 (67.9%) 92 (83.6%) .020
Age$  70.4 ± 8.1 68.5 ± 9.2 73.2 ± 8.1 .000
Skin type (Fitzpatrick) 
 Type 1
 Type 2
 Type 3
35 (34%)
62 (60.2%)
  6 (5.8%)
27 (25.7%)
69 (65.7%)
  9 (8.6%)
13 (11.8%)
87 (79.1%)
10 (9.1%)
.004
History 
 Bowen’s disease
      - 1 or more 
 Basal cell carcinoma
      - 1 or more
 Squamous cell carcinoma
      - 1 or more
23 (22.1%)
 
39 (37.5%)
  
15 (14.4%)
7 (6.6%)
  
25 (23.6%)
  
9 (8.5%)
18 (16.4%)
    
34 (30.9%)
24 (21.8%)
.006
.091
.023
AK - Olsen (grade)
 1
 2
 3
71 (68.3%)
31 (29.8%)
  2 (1.9%)
60 (56.6%)
40 (37.7%)
  6 (5.7%)
64 (58.2%)
35 (31.8%)
11 (10.0%)
.079
AK Location
 Scalp
 Face
 Face & scalp
22 (21.2%)
54 (51.9%)
28 (26.9%)
36 (34.0%)
63 (59.4%)
  7 (6.6%)
48 (43.6%)
56 (50.9%)
  6 (5.5%)
.000
AK
 Number of lesions$
 Number lesions/size area 
(mm)$
32.48 ± 18.38
0.15 ± 0.06
20.22± 16.00
0.14 ± 0.10
22.78± 15.67
0.11 ± 0.06
.000
.000
Previous treatment 62 (59.6%) 45 (42.5%) 61 (55.5%) .034
Cosmetic score$ 4.47 ± 2.64 4.29 ± 2.24 5.37 ± 2.74 .005
Co-morbidity 2.21 ± 1.81 1.76 ± 1.56 1.70 ± 1.44 .097
$ mean and standard deviation
Table 2   Lesion reduction of actinic keratoses in patients treated with 
methylaminolaevulinate photodynamic therapy (MAL-PDT), imiquimod 
cream (IMI) and 5-fluorouracil cream (5-FU) 
MAL-PDT IMI 5-FU
Number of lesion reduction at:
 M3 (absolute numbers (SD)) 23.90 (14.6) 15.70 (13.0) 19.66 (13.8)
 M12 (absolute numbers (SD)) 25.81 (16.3) 15.14 (11.9) 19.34 (13.6)
Mean percentage of lesion reduction at:
 M3 (% (SD)) 79.39 (22.3) 80.00 (24.7) 89.53 (18.9)
 M12 (%(SD)) 81.12 (22.4) 81.65 (23.4) 88.45 (15.8)
Total number of full responders at:
 M3 (n (%)) 24 (25.8) 34 (34.0) 52 (54.2)
 M12 (n (%)) 19 (20.7) 35 (36.1) 37 (41.1)
SD = standard deviation, M3 = 3 months after treatment, M12 = 12 months after treatment
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Discussion
The present study demonstrates which treatment patients with multiple AKs currently 
receive in real-life clinical situations, how these patients fare in terms of lesion load and 
cosmetic outcome, and what costs are incurred. 
 Differences were found in patient characteristics between the treatment groups. 
Patients who were much more severely affected with number of AKs, who had had more 
previous treatments, and a higher overall number of previous skin tumours, were more 
often treated with MAL-PDT. We also noted more co-morbidities in this patient group. 
The youngest patients, who were least severely affected by AKs and previous treatments 
were more frequently treated with IMI. Male patients, those of older age, with more 
previous SCCs, and worse cosmetic scores at M0, were most often treated with 5-FU. 
 MAL-PDT is registered for AK treatment when other treatments are considered less 
appropriate. Therefore, it is not surprising that patients in the PDT group were more 
severely affected and had had more previous treatments. Compared with patients 
treated with IMI, the number of AKs was 60% higher in the PDT group, compared with 
patients treated with 5-FU, the number of AKs was 43% higher in the PDT group. It is well 
known that these AK fields (field cancerization) are more difficult to treat and have a 
higher potential for recurrence, and that multiple initial treatments are recommended in 
these patients13-15. The higher number of previous treatments in the PDT patient group 
may thus be a consequence of rapid recurrences and/or therapy-resistant AK. 
 Another difference between PDT and the other treatments is that PDT is an 
in-hospital treatment. Patients who are unwilling or unable to treat themselves with IMI 
or 5-FU will choose PDT. This may explain the larger treatment area and the higher 
number of co-morbidities in the MAL-PDT group, since these might be patients who 
prefer more assistance with their treatment.
With respect to consumption of care, it was found that patients treated with MAL-PDT 
had more pre-treatment consultations. This may be because one of the university 
hospitals planned a standard pre-PDT visit for instructions. This is not standard in other 
hospitals. Furthermore, treatment costs for MAL-PDT were the highest. This is mainly due 
to the high costs of MAL cream and costs related to day-care admission. In patients with 
large treatment areas, multiple appointments were necessary to treat all lesions. 
The number of full responders in the present study is lower than in previous clinical 
trials11,16. This may be because there is a striking difference in the number of AKs at 
baseline (approximately 7 in previous studies, compared with approximately 25 in the 
present study). An earlier study from our group, in which patients with AK were treated 
with MAL-PDT, showed that patients in whom therapy failed, had significantly higher 
numbers of AK at baseline13. This may have an important influence on overall efficacy. 
Table 3   Number of subsequent treatments during 1-year follow-up (n(%))
MAL-PDT
n=91
IMI
n=96
5-FU
n=92
Cryotherapy* 71 (78.0) 68 (70.8) 55 (59.8)
5-FU* 8 (8.8) 3 (3.1) 12 (13.0)
IMI* 5 (5.5) 13 (13.5) 2 (2.2)
MAL-PDT* 11 (12.1) 2 (2.1) 1 (1.1)
Total * 75 (82.4) 71 (74.0) 61 (66.3)
* % per treatment group
MAL- PDT = methylaminolaevulinate photodynamic therapy, IMI = imiquimod cream, 5-FU = 5-fluorouracil 
cream
Table 4   Costs (€) per treatment group; methylaminolaevulinate photodynamic 
therapy (MAL-PDT), imiquimod cream (IMI) and 5-fluorouracil cream (5-FU). 
(mean ± SD)
MAL-PDT IMI 5-FU
Outpatient clinic visits 754.31 ± 275.58
(198.99 – 1604.40)
627.55 ± 26.36
(265.32 – 1203.30)
590.74 ± 27.54
(198.99 – 1337.0)
Biopsies 22.80 ± 9.54
(0.0 – 781.7)
12.26 ± 6.04
(0.0 – 469.02)
21.67 ± 6.97
(0.0 – 312.68)
Treatment 984.11 ± 56.60
(0.0 – 2704.41)
99.50 ± 4.50
(59.59 – 238.36)
41.14 ± 0.0
(41.14 – 41.14)
Concomitant treatment 4.73 ± 1.13
(0.0 – 47.69)
2.34 ± 0.51
(0.0 – 24.40)
2.55 ± 0.43
(0.0 – 24.50)
Subsequent treatment 180.83 ± 25.30
(0.0 – 1432.38)
130.48 ± 22.60
(0.0 – 1550.25)
79.98 ± 10.03
(0.0 – 538.58)
Total 1949.90 ± 75.52
(534.34 – 4127.83)
877.17 ± 43.49
(329.98 – 3332.72)
738.41 ± 34.29
(306.46 – 1875.20)
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 Since all treatments appeared to be effective in the different treatment groups, 
patient characteristics and costs could play an important part in treatment choice. Since, 
at present, MAL-PDT is regarded as a costly treatment, this therapy is preferred for specific 
cases, e.g. patients with extensive or therapy-resistant field cancerization, or who are not 
compliant or able to perform treatment at home. Otherwise, 5-FU appears to be the least 
costly treatment that is effective in cases of multiple AK.
Furthermore, the follow-up period and treatment regimen were different from previous 
trials. The official treatment protocol for 5-FU prescribes a single treatment session, 
whereas for MAL-PDT and IMI an additional session after evaluation may be part of the 
initial treatment session. In our study it was found that, in clinical practice, cryotherapy is more 
often used as a subsequent treatment instead of an additional cycle of MAL-PDT or IMI. 
Compared with previous studies of field-treatment for AK, different costs were found. In a 
study by Annemans et al. 5 cost per AK lesion after 6 months’ follow-up and treatment 
with MAL-PDT was €58. Other studies performed were based on a decision analytical 
approach or assumptions on the number of treatments6,7. Except for Gold’s study, in 
which a standard second treatment cycle was calculated, treatment costs in the literature 
were lower than the costs found in our study. Although the published studies were 
performed in other countries, additional factors may explain the differences in costs. Only 
one of these studies is observational, with a follow-up of only 6 months5. In addition, a 
smaller spectrum of costs was included (e.g. no subsequent treatment, no treatment of 
recurrences). Moreover, patients in the present study were more severely affected.
The aim of our study was to assess the costs and effectiveness of the various treatment 
modalities as used in clinical practice for patients with multiple AK. The appropriate 
design for such a study is an observational longitudinal study, monitoring treatment 
effects and costs as they arise in practice. The disadvantage of such a design is that many 
patients received additional treatment for their AK, as AK is a chronic and recurrent 
disease, therefore the reduction in lesion number at M12 was influenced by subsequent 
treatments. However, our aim was not to demonstrate the efficacy of a single treatment 
modality alone.
 Another limitation may be the fact that the number of AKs assessed at M3 and M12 
were all AKs present in the treatment area, including new lesions. Other study designs 
mainly assessed the response and recurrences of specific lesions. However, to calculate 
the costs for field-directed treatment in patients with multiple lesions, it is more 
appropriate to include all lesions appearing in the treatment area, since they all need 
treatment. 
Conclusion
The present observational study shows that, in real-life clinical practice, patients with AK 
are more severely affected than patients in clinical trials and that the costs of field-directed 
treatment are much higher. This is caused mainly by the high number of AKs and the 
wider range of costs included in our study. New developments, e.g. daylight PDT for 
individual cases, may reduce these costs in the future.
104 105
CHAPTER 5 PATIENT CHARACTERISTICS, COST AND EFFECTIVENESS OF ACTINIC KERATOSIS TREATMENT
5
Literature
1 Flohil SC, van der Leest RJ, Dowlatshahi EA, Hofman A, de Vries E, Nijsten T. Prevalence of actinic keratosis and 
its risk factors in the general population: the Rotterdam Study. J Invest Dermatol 2013; 133: 1971-1978.
2 Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a 
Merseyside population. Br J Dermatol 2000; 142(6): 1154-1159.
3 Schaefer I, Augustin M, Spehr C, Reusch M, Kornek T. Prevalence and risk factors of actinic keratoses in 
Germany - analysis of multisource data. J Eur Acad Dermatol Venereol 2014; 28: 309-313.
4 Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H et al. Development of a treatment algorithm 
for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18(6): 651-659.
5 Annemans L, Caekelbergh K, Roelandts R, Boonen H, Leys C, Nikkels AF et al. Real-life practice study of the 
clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) 
in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol 2008; 18(5): 539-546.
6 Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol 2008; 
7(1): 23-25.
7 Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog 
Treat 2009; 20(5): 266-275.
8 Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL et al. Risk of serious 
adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs 
eligible for randomized controlled trials. Arch Dermatol 2012; 148(4): 463-470.
9 CBS statline [Accessed 2014 Sep 16 ]. Available from: http://statline.cbs.nl/StatWeb/publication/? DM=SLNL &PA=71 
311 ned&D1=0&D2=0&D3=12,38,51,64,77,90,103,116,129,142,155,168,181,194,219,232&HDR=T&STB=G2,G1&VW=T. 
10 Hakkaart-van Roijen L., Tan S.S., Bouwmans C.A.M. [Guideline for cost-effectiveness studies.] [last viewed on 
2014 Sep 16] Available from:http://www.cvz.nl/binaries/content/documents/zinl-www/documenten/publicaties/ 
overige-publicaties/1007-handleiding-voor-kostenonderzoek/Handleiding+voor+kostenonderzoek.pdf. 
11 Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% 
imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a 
comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157 Suppl 2: 
34-40.
12 Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two 
treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. 
Acta Derm Venereol 2005; 85(5): 424-428.
13 Kleinpenning MM, van de Kerkhof PC, Gerritsen RM. The clinical efficacy of topical methyl-aminolevulinate 
photodynamic therapy in moderate to severe actinic keratoses of the face and scalp. J Dermatolog Treat 
2010; 21(4): 252-257.
14 Wennberg AM, Stenquist B, Stockfleth E, Keohane S, Lear JT, Jemec G, Mork C, Christensen E, Kapp A, Solvsten 
H, Talme T, Berne B, Forschner T. Photodynamic therapy with methyl aminolevulinate for prevention of new 
skin lesions in transplant recipients: a randomized study. Transplantation 2008; 86: 423-429.
15 Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA.Topical photodynamic therapy for prevention of new skin 
lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-28.
16 Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I et al. Intraindividual, right-left comparison of topical 
methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a 
multicentre, randomized controlled study. Br J Dermatol 2006; 155(5): 1029-1036.
Summary and discussion
6
109
SUMMARY AND DISCUSSION
6
Summary and discussion
In this thesis outcomes of (observational) studies on skin cancer (SC) practice in primary, 
secondary and tertiary care in the Netherlands have been described. Data of studies 
performed in primary care were obtained from a questionnaire, referral letters and 
pathology reports. To provide insight in SC practice in secondary and tertiary care, real-life 
patient data were collected and pathology reports were analysed. In this chapter a 
summary of the main conclusions is written, based on the aims provided in chapter 1, 
followed by a discussion. 
1.   To investigate the tumour characteristics of NMSC populations in different 
hospital settings
Most studies on the incidence and prevalence of non-melanoma skin cancer (NMSC) 
report the number of patients with a skin tumour. Studies on the number and types of 
skin cancer per patient are rare. We studied a patient population with field actinic 
keratosis (AK) in the face and scalp region (population described in chapter 5) or with 
nodular or superficial basal cell carcinomas (BCCs). These patients could have presented 
themselves with a skin tumour for the first time, or may have had a history of previous 
skin tumours. Combining the complete number of tumours that developed during a 
two-year follow-up (FU) with those from the patients’ history, we found that 47.1% of our 
population had more than one malignancy. Furthermore, 59.9% had more than one type 
of (pre-)malignancy. In another Dutch study, 2106 tumours were diagnosed in 876 
patients between 2004 and 20101. Two or more tumours occurred in 406 (46%) patients. 
The second tumour developed within a median FU of 5 months. In this, as well as in our 
study, it was found that half of the ‘in-hospital SC population’ did develop at least a 
second skin cancer, mainly BCC. From these numbers it may be concluded that SC should 
be regarded as a chronic disease. Furthermore, the question arises how FU should be 
performed in the near future. The present Dutch BCC guideline does not advise FU for 
patients with a single BCC, except if it concerns a high risk BCC2. Therefore, patients who 
are discharged from FU should be advised in self testing of their skin and be aware that 
additional tumours could occur. Additionally, in the near future, general practitioners 
(GPs) could play a role in the FU of low-risk SC patients.  
As mentioned in chapter 2, patients included in our study are only a selection of the 
total SC population. Therefore, to provide a complete overview of the burden of SC in 
hospital patients, or in primary care as well, complete registration of all (pre-)malignant 
tumours should be performed. Attempts to register NMSC in a database have been 
performed in Denmark3. Their conclusion was that the NMSC database had the potential 
to become a resource for epidemiological research of NMSC, however improvement was 
necessary, since registration was not complete.
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 In chapter 3.2 the results of an analysis of 734 referral letters of GPs are described. In 
only 1.2% of these referrals, a biopsy was performed. A much lower percentage as 
compared to the percentages indicated in the questionnaires. This low number may be 
explained by the fact that the referrals did not only include NMSC and that referred 
patients might form another population than those treated in primary care. Furthermore, 
in the population of referred patients, letters of all referring GPs were included, in the 
questionnaire there may have been a selection of GPs responding who have a special 
interest in dermatology and therefore take biopsies more often. 
 With respect to the clinical diagnostics of skin tumours, we found a correct diagnosis 
mentioned in 39.8% of referral letters. In an evaluation of 1898 analysed pathology reports 
in chapter 3.3, GPs correctly diagnosed 21.6% of BCC, 0% of SCC, and 8.7% of melanomas. 
Although SCC and melanoma are preferably not treated in primary care, GPs should be 
able to recognise these tumours to refer them to dermatologists. With respect to the 
quality of referrals we found that out of 38 confirmed SCCs, only six were referred as SCC. 
In only 15.4% of referral letters, an adequate lesion description by using dermatological 
terminology was performed. The latter is an important finding, since adequate lesion 
description helps the dermatologist to triage referred patients, especially in cases where 
correct referral diagnoses are missing. 
 A limitation of the analysis of referral letters is that it does not provide a complete 
picture of the SC management as it is performed in primary care. Therefore, also 
pathology reports of skin tumour material collected by GPs were analysed (chapter 3.3). 
The most common used methods were: once-off excision (excision without previous 
biopsy) (58.4%), shave/curettage (22.3%), and diagnostic biopsies (17.9%). After 
pathological investigation, almost 90% of these tumours were diagnosed as benign, 
indicating that GPs excise high numbers of benign lesions using once-off excision. On the 
other hand, GPs did not excise SC very often; in total159 NMSC (mainly BCC, SCC, BD, and 
AK) (< 1 per GP) and 1 melanoma for every 7 GPs. This could also be an explanation for 
the fact that the rate of incomplete excisions was substantial: 65.4% located in the face 
and neck region, 29.5% on the trunk, and 10.7% on the extremities. The fact that GPs have 
difficulties with complete excisions of skin malignancies has been confirmed by previous 
foreign studies as well. In a British study, margin involvement with tumour was present in 
68% (15/22) of excision biopsies performed by GPs in melanoma, BCC and dysplastic 
naevus10. Unfortunately lesion location was not mentioned. In a Scottish study, it was 
found that GPs excise smaller lesions as compared to dermatologists, perform less 
diagnostic procedures, and have an incomplete excision rate for skin cancer of 23.1%, 
with the highest for melanomas (34.6%)11.
 With regard to the current screening and FU skills of GPs, in our questionnaire it was 
found that total body (TB) examination is performed by 34% of GPs in case of BCC and by 
19% in case of SCC. Twenty-seven percent of GPs is familiar with the FU guidelines for 
BCC. With regard to the fact that many patients develop multiple (pre-)malignancies, as 
A complete registration of (pre-)malignancies of the skin could also be useful in the 
financial compensation of SC care. At present, an established maximum is paid for the 
diagnosis and FU of SC patients. This may be sufficient in case of ‘regular’ SC patients with 
a few skin tumours. However, as described in chapter 2, we found that 10.8% of patients 
included in university hospitals had > 10 malignancies. In clinical practice it is noticed that 
some of these patients may present themselves with high numbers of tumours at once. 
For this selected patient population the question arises whether the current compensation 
rate is sufficient for diagnostics, treatment, and FU needed for these patients.  
2a.  To investigate the present role and skills of GPs in skin cancer care
GPs perform a gatekeeper role in Dutch healthcare. From this position they are the first to 
see a patient with SC. Therefore adequate recognition of SC, appropriate treatment and/
or adequate referral is important. Additionally, GPs could play a significant role in both 
primary and secondary prevention by means of sun protection advice and total body 
inspection of patients with sun damaged skin. Up till now, Dutch studies to assess the 
present role and skills of GPs in SC care are scarce. In chapter 3, three paragraphs are 
devoted to this theme. 
 As stated in chapter 3.1, GPs do request additional SC training, mainly with respect 
to diagnosing Bowen’s disease (BD), squamous cell carcinoma (SCC) and melanoma. 
However, it was also found that only 3% of GPs believed that SCC treatment should 
actually be carried out in primary care. Furthermore, in case of a melanoma, the Dutch 
guideline recommends GPs to refer patients to a dermatologist4. 
 With respect to AK, 75%, and with respect to BCC, 20% of the GPs believe that 
treatment should be performed by GPs. An additional 33.2% would treat low-risk BCC 
themselves. 
 When evaluating current practice in primary care, the most commonly used AK 
treatment is cryotherapy, followed by 5-fluorouracil (5-FU) cream (16%) and imiquimod 
(IMI) (9%). In case of suspicion of BCC 9.7% would perform a biopsy; 42.2% would perform 
an excision; IMI and (referral for) photodynamic therapy (PDT) in case of BCC are used by 
9.3%. These low numbers indicate that GPs are not familiar with topical treatments for AK 
and low risk BCC. Our findings are in line with data from a previous study performed in 
seven different countries5. In this study, 31% of primary care physicians would treat BCC, 
80% would refer these patients to a dermatologist. The first choice for BCC treatment was 
surgical therapy, the first choice for AK treatment was cryotherapy. In the same study, 
more than 80% of dermatologists and primary care physicians reported that the main 
factors affecting treatment choice for BCC and AK were personal skill level, efficacy, 
recurrence rate, and cosmetic results. Therefore, low frequency of topical therapy use in 
primary care for AK and BCC treatment may be caused by a lack of knowledge and 
experience. Training of GPs would thus be necessary, since it is known that topical 
treatments are (cost-)effective and have excellent cosmetic results6-9. 
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 In order to improve treatment skills in primary care, diagnostic skills should be 
improved as well, to make sure GPs are aware of the type of tumour they are confronted 
with. The data presented in chapter 3 point out that GPs have difficulty with clinical 
diagnosing (pre-)malignancies of the skin. By analyzing referral letters it was also found 
that half of the referrals included benign lesions and only half of the patients referred 
under suspicion of a BCC actually had a BCC. Additionally, out of 125 seborrhoeic keratoses 
diagnosed by the dermatologists, 42 were referred as atypical naevi. These findings are 
supported by previous studies, which also demonstrated the difficulties of GPs with 
diagnosing skin cancer15-18. 
 Furthermore, GPs do not use diagnostic tools on a large scale19. Performing biopsies 
in NMSC has educational value, as the results will give adequate feedback on the clinical 
diagnosis. Furthermore, it lowers the number of unnecessary referrals and excisions of 
benign lesions. Dermatoscopic investigation is another helpful tool, although primarily in 
trained hands. It helps to differentiate between pigmented lesions20-22. Training in 
dermoscopy for the most common lesions (nevi, seborrhoic keratoses, angioma) may 
lower the number of referrals of seborrhoeic keratoses mistaken for naevi and may also 
prevent unnecessary excisions of benign lesions. 
 With respect to treatment of skin tumours in primary care, improvement can be 
made with adjustment and education in a few areas. As discussed previously, GPs mainly 
excise benign lesions with primary excision. The number of these excisions could be 
reduced by increasing the use of shave or curettage. These treatments are less invasive, 
and in case of diagnostic doubt material for histological evaluation is available. The 
number of excisions may be further lowered by the use of topical agents in the treatment 
of superficial BCC (sBCC). In previous studies it has been shown that the use of topical 
creams is cost-effective 6,7. More widespread use of topical agents for patients with 
multiple AKs in primary care lowers referrals to dermatologists and contributes to 
prevention of SCC. As described in chapter 5, both 5-FU and IMI are effective treatments 
that may be used by GPs in the treatment of field AK. Recently, also ingenol mebutate 
became available for topical treatment of AKs.
 With respect to the surgical treatment of SC, GPs are advised to be aware of their 
own surgical abilities. As discussed in chapter 3.3, excisions performed by GPs are often 
incomplete, especially in the face. Data presented in this chapter is an average of 161 GPs. 
There may be differences between individual GPs. However, since the number of 
incomplete excisions in the face and neck region is very high, GPs are advised to refer 
tumours in this area to a dermatologist. Furthermore, for those who want to perform 
excisions in primary care, additional training with respect to surgical techniques and 
knowledge on guidelines (e.g. surgical margins) should become available. 
As discussed in chapter 2, multiple (pre)malignancies per patient are found in more than 
half of hospital SC patients. The question arises whether the follow-up of all SC patients 
described in chapter 2, and the fact that SC also occurs on infrequently UV exposed 
skin12 it could be seen as an inaccurateness that not all these patients are screened by 
means of TB examination, especially in those who are not referred to a specialist. Failure 
to perform total body examination could result in one in three of melanomas being 
missed13. The lack of performance of TB examination on a large scale is also discussed in 
chapter 3.2 in which the finding of 234 additional premalignant and malignant lesions 
by dermatologists after referral are reported. Most of these patients were referred with a 
single lesion on the face or scalp; tumours that can be seen without the patient being 
undressed.  
 An encouraging finding was the fact that risk factors for development of SC were 
known by 93% of GPs. However, additional knowledge on risk factors is requested by 
70.5%. If education results in an increase in UV protection advice, this is very worthwhile, 
since it has been proven that, if mediated personally by a GP, sun protection advice can 
lead to an improvement in sun protection over a prolonged time period14. 
A limitation of the study on the skills of GPs in SC care is the fact that these data are based 
on patients in which action was taken. The numbers described in chapter 3.2 and 3.3 
are those collected from patients that have been referred or from whom material was 
collected for pathological investigation. Missing data are those of patients in whom no 
action was undertaken, patients who were incorrectly diagnosed or in case no 
pathological investigation was performed after excision. To provide complete insight in 
their current skills and role in SC care, GPs should be followed prospectively during their 
practices. This type of research is difficult to perform. 
2b.  To explore the future role of GPs in SC care
When speculating on the future role of GPs in SC care, data on GPs current role (as 
discussed at aim 1a) should be considered. Furthermore, additional data as described in 
chapter 3 will be summarised below.
 In a questionnaire assessing the future role of GPs in SC care (chapter 3.1) 93.7% 
indicated that they judge SC as a health problem in which GPs should play a role, 86.0% 
would like to play a larger role themselves. This is very encouraging since the cornerstone 
of the extension of GPs future role in SC care is based on their willingness to participate. 
 As mentioned previously, 89.2% of GPs treat AK themselves already. This number 
does not seem to increase after additional education, most likely, because for GPs who 
treat AK already, additional education would not make a difference. However, most GPs 
treat AKs only with cryotherapy, whereas in case of multiple AKs, topical (field) treatment 
is more appropriate.
 The number of GPs that would treat BCC after additional education is 51.9%, for BD 
this is 42.2%. The percentage of GPs that would treat SCC or melanoma after education 
remains, as can be expected, low (resp. 19.8% and 2.2%). 
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 Based on our data it is difficult to decide whether or in which cases a diagnostic 
biopsy can be omitted in the future. To provide more insight in the effectiveness and 
efficiency of a diagnostic biopsy, a prospective study should be performed.
 The discussion of the necessity of a biopsy prior to excision is mainly relevant in 
dermatological practice. Although not directly investigated, it seems justified to conclude 
that in case of suspicion of a BCC in primary care, as discussed in chapter 3, a biopsy is 
recommended since the accuracy of clinical diagnosis by GPs in much lower as compared 
to dermatologists.      
4.  To investigate patient characteristics, efficacy, and costs in patients with field AKs 
Previous studies have been performed to provide insight in the costs and efficacy of field 
treatment for AK. However, most of these studies are based on randomised clinical trials 
in patients with few AKs, providing data which are not applicable in the real-life 
situation27-30. 
 In chapter 5 we provided an overview of real-life clinical data of 320 patients treated 
for field AK in an observational multicenter study. All patients included had AK on the face 
and/or scalp suitable for field directed treatment with methyl aminolevulinate 
photodynamic therapy (MAL-PDT), IMI or 5-FU. 
 With respect to patient characteristics documented at baseline, significant 
differences between the treatment groups were found. Patients in the MAL-PDT group 
had the highest number of previous treatments, highest percentage of both face and 
scalp affected, and significant higher numbers of AK lesions. Those treated with IMI were 
most often females, with the lowest age, and lowest number of AK lesions. The latter is 
not that surprising since IMI may only be performed in small fields. Patients in the 5-FU 
group were most often males, with the highest age, and the highest number of previous 
SCC. The treatment choice was made by both the dermatologist and the patient, based 
on the (dis)advantages of each treatment. This may explain some of these baseline 
differences. As PDT is registered for AK treatment when other treatment options are less 
appropriate, this treatment may have been chosen more often after insufficient efficacy 
of previous therapies, explaining the higher number of previous treatments in the 
MAL-PDT group. Furthermore, PDT is an in-hospital treatment and treatment is finished 
after one single visit. This might explain the fact that patients with higher AK numbers 
and larger affected areas chose PDT. 
 The mean number of AKs in the treatment groups was 32 for MAL-PDT, 20 for IMI, 
and 23 for 5-FU. These numbers also indicate, as mentioned in chapter 2 as well, that in 
real life, the NMSC population is more severely affected as compared to patients treated 
in clinical trials.
 As the purpose of our study was to collect real-life clinical data, we chose to perform an 
observational study. This led to significant differences between the baseline characteristics 
of the treatment groups, as described above. Therefore, data on effectiveness and cost 
should be performed in hospital settings. A future role of GPs in SC care may also include 
the FU of patients with low risk BCC and/or AK. However, in this case GPs should use 
guidelines and perform total body examination.
3.  To investigate the value of a diagnostic incision biopsy in BCC
To diagnose BCCs, a diagnostic biopsy is recommended. Previous studies have been 
performed to investigate the concordance between the BCC subtype diagnosed in 
biopsy specimen as compared to the subsequent excision23-25. These studies show an 
agreement of 60.9%-72.3%, due to sampling error in which the most aggressive subtype 
is missed. In chapter 4 an overview is presented of the completeness and efficiency (in 
time) of excised BCCs with and without previous biopsy, performed by dermatologists. A 
total of 357 excisions after biopsy and 844 once-off (without previous biopsy) excised 
BCCs were evaluated. In 84.2% of all lesions excised under suspicion of BCC, this diagnosis 
was pathologically confirmed. 
 With respect to the completeness of excisions no significant difference (P = 0.179) 
was found between BCCs excised after biopsy and once-off excised BCCs. When 
analysing subgroups, in nodular BCCs (nBCC) significantly (P = 0.047) more excisions after 
biopsy were complete. Due to the retrospective design of the study, there was no 
explanation found for this difference, since we could not obtain data on excision margins 
used, exact tumour location and tumour size. Furthermore, we were not able to provide 
insight in the considerations made by the dermatologists when choosing the used 
procedure. 
 In the group of incompletely excised infiltrative BCCs (iBCCs), a significant higher 
number of disagreement in BCC subtype was found between the biopsy and the 
excision. This could indicate that the performance of a biopsy with sampling error in this 
subgroup misled the dermatologist to use an incorrect margin which led to an 
incomplete excision. 
 With respect to the efficiency of a once-off excision it was found that, with a mean 
excision time of 13 minutes, a once-off excision is more efficient if performing a biopsy 
would take more than 1.94 minutes. Since excision time may differ per tumour, a two-way 
sensitivity analysis was performed to provide insight into the most efficient strategy, 
dependent on the excision and biopsy time (chapter 4). In this comparison only the 
doctors’ time to perform a biopsy/excision was included. In clinical practice there are 
more factors to consider, e.g. the time of the nurse spend on the biopsy or excision, the 
additional time spend on a phone call or visit after biopsy, and the costs of the biopsy.
 In some specific cases a diagnostic biopsy is relevant for treatment choice, e.g. in 
cases when topical treatment is considered in sBCC, or in case Mohs micrographic surgery 
or radiotherapy is considered in high risk or difficult to excise BCC. Especially since the 
diagnostic ability of a biopsy is still better than the clinical diagnosis of the dermatologist 
in sub-typing a BCC26. 
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are described per group instead of being compared between groups. The mean 
percentage of lesion reduction after 3 months was 79.4% for MAL-PDT, 80.0% for IMI and 
89.5% for 5-FU. After 12 months this was resp. 81.1%, 81.7%, and 88.5%. It should be noted 
that most patients received additional treatment if necessary and not all patients received 
a second cycle of the initial treatment in case of remaining AK. We found that in clinical 
practice, if only few AK had to be treated, cryo-therapy was the first choice of subsequent 
treatment. This deviates from PDT and IMI treatment protocols in which, in case of residual 
lesions, an additional cycle of treatment is advised. However, in real-life practice the 
choice for additional cryotherapy is cheaper and faster than an additional cycle of IMI or 
PDT. 
 With regard to the treatment and FU cost over one year, we found mean costs of 
€1949.90 for MAL-PDT, €877.17 for IMI, and €738.41 for 5-FU. Compared to a previous study 
performed in Belgium, total cost including 6 months FU were €381 for MAL-PDT31. 
However, in the Belgian study a  shorter FU time with less additional treatment costs was 
performed, a mean of 7.1 AK per patient was found, and no cost for day-care admission 
were calculated. 
 Based on patient characteristics, efficacy of treatment and cost, we conclude that 
MAL-PDT should be used for a specific patient population, e.g. patients with extensive AK, 
in whom previous therapies have failed or who are not capable to use treatments at 
home. 
Conclusion and future perspective
Skin cancer patients, when investigated in real-life clinical practice are more severely 
affected than those in clinical trials. Thus, results from clinical (randomised) studies may 
not be appropriate in real-life clinical practice. Observational studies performed in the 
real-life situation may contribute to this lack of information and personalized medicine.
 Adequate registration of the complete number of (pre-)malignancies of the skin is 
necessary to create a realistic overview of the extensiveness of the SC problem. 
 Additional skin cancer training for GPs and GPs in training should precede the shift 
from low risk skin cancer care to the primary care setting. Although GPs are willing to play 
a more extensive role in SC care, their diagnostic ability and use of diagnostic tools should 
be extended. Furthermore, education on treatment regimes and accompanying 
protocols should be available in general practice. 
 In secondary and tertiary care further evaluation of the additional value of punch 
biopsies in the diagnosis of BCC could contribute to efficiency of care and reduction of 
cost. When choosing a field directed treatment in AK, patient characteristics should also 
be considered, leading to better cost-effectiveness.
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Nederlandse samenvatting en discussie
In dit proefschrift zijn de uitkomsten van (observationele) studies naar de huidkanker zorg 
in de eerste, tweede en derde lijn in Nederland beschreven. Data uit de eerste lijn werd 
verkregen door middel van analyse van vragenlijsten, verwijsbrieven en pathologie 
verslagen. Om inzicht in de huidkankerzorg in de tweede en derde lijn te verkrijgen 
werden patiëntgegevens en pathologieverslagen verzameld. In een groot deel van deze 
studies werd ‘real-life clinical data’ gebruikt, wat betekent dat de verzamelde data zoveel 
mogelijk een afspiegeling van de dagelijkse praktijk vormen. In dit hoofdstuk wordt een 
samenvatting van de belangrijkste uitkomsten van deze onderzoeken gegeven, gevolgd 
door een discussie. Het hoofdstuk is opgebouwd uit verschillende onderzoeksvragen 
welke wij hebben getracht te beantwoorden. 
1.   Het in kaart brengen van de tumorkarakteristieken van patiënten met NMSC in 
verschillende soorten ziekenhuizen. 
De meeste studies die gedaan zijn naar de incidentie en prevalentie van niet-melanomen 
huidkanker (NMSC) vermelden het totaal aan patiënten dat huidkanker krijgt. Studies naar 
het aantal tumoren en de verschillende soorten tumoren per patiënt zijn minder 
beschikbaar. Wij hebben een populatie van patiënten bestudeerd die geïncludeerd 
waren in een studie vanwege aanwezigheid van multipele actinische keratosen (AK) (de 
populatie zoals beschreven in hoofdstuk 5) of een nodulair of superficieel basaalcel-
carcinoom (BCC). Deze patiënten konden nieuwe patienten zijn, die zich voor de eerste 
keer met huidkanker presenteerden, of waren al jaren onder controle vanwege eerdere 
huidtumoren. Het aantal tumoren van deze patiënten, uit een twee jaar durende 
follow-up (FU), werd opgeteld bij de tumoren uit het verleden. Hierbij vonden we dat 
47.1% van deze patiënten meer dan één maligniteit had ontwikkeld. Daarnaast had 59.9% 
meer dan één soort (pre-)maligniteiten ontwikkeld. In een andere Nederlandse studie 
werden 2106 tumoren gediagnosticeerd bij 876 patiënten tussen 2004 en 20101. In 406 
(46%) van deze patiënten werden twee of meer tumoren gevonden. De tweede tumor 
ontwikkelde zich met een mediane FU van 5 maanden. In deze studie, alsmede in onze 
eigen studie, werd gevonden dat van patiënten met huidkanker uit de ziekenhuispopula-
tie de helft een tweede tumor ontwikkelt, meestal zijn dit BCCs. Hieruit kunnen we 
concluderen dat huidkanker als een chronische ziekte gezien kan worden. 
 Daarnaast is het de vraag hoe de vervolgcontroles van deze patiënten in de toekomst 
georganiseerd dienen te worden. In de huidige Nederlandse BCC richtlijn wordt 
geadviseerd om patiënten na een enkel BCC uit de controle te ontslaan, tenzij er sprake is 
van een hoog risico tumor2. Deze patiënten zouden geadviseerd kunnen worden om zelf 
onderzoek van de huid te doen en hen erop te wijzen dat er een reële kans is op het 
ontstaan van een tweede tumor. Daarnaast zouden huisartsen een rol kunnen spelen in 
de FU van patiënten met laag risico tumoren. 
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 Met betrekking tot de behandeling in de huisartsenpraktijk vonden we dat 
cryotherapie de meest gebruikte methode is in geval van AKs, gevolgd door 5-fluorouracil 
(5-FU) crème (16%) en imiquimod (IMI) (9%). In het geval van verdenking op een BCC zou 
9.7% een biopt nemen en zou 42.2% een excisie verrichten. IMI en (verwijzing voor) 
fotodynamische therapie (PDT) zou door 9.3% van de huisartsen ingezet worden. Deze 
lage percentages laten zien dat huisartsen niet uitgebreid bekend zijn met het gebruik 
van topicale behandelingen voor AKs en laagrisico BCCs. Deze bevindingen worden 
ondersteund door data van een eerder verrichte studie in 7 verschillende landen5. Deze 
studie liet zien dat 31% van de huisartsen een BCC zou behandelen en 80% de patiënt 
naar de dermatoloog zou verwijzen. Hun voorkeursbehandeling voor BCC was excisie, 
voor AK was dit cryotherapie. In dezelfde studie werd door meer dan 80% van de 
dermatologen en huisartsen aangegeven dat de belangrijkste factoren in het maken 
van de behandelkeuze bij AK en BCC het volgende waren: niveau van persoonlijke 
vaardigheden, effectiviteit, recidiefkans en cosmetisch resultaat. Het lage aantal 
huisartsen dat AK en BCC met topicale therapie behandelt in onze studie zou daarom 
verklaard kunnen worden door een gebrek aan ervaring (en dus ook vaardigheden) met 
deze middelen. Training van huisartsen met topicale middelen wordt daarom 
geadviseerd, aangezien bekend is dat deze middelen (kosten)effectief zijn en cosmetisch 
goede resultaten geven6-9. 
 In paragraaf 3.2 worden de resultaten beschreven van een analyse van 734 
verwijsbrieven van huisartsen aan de dermatoloog. Bij slechts 1.2% van de verwezen 
patiënten met huidtumoren was voorafgaand een biopt genomen. Dit is een lager 
percentage dan wat de huisartsen in de enquête hadden aangegeven. Een verklaring 
hiervoor kan zijn dat de verwezen patiënten niet alleen maar NMSC hadden en dat deze 
populatie anders van samenstelling is dan die van patiënten die in de eerste lijn worden 
behandeld. Daarnaast bestaat er een kans dat de huisartsen die de enquête hebben 
geretourneerd niet geheel representatief zijn voor de totale huisartsen-populatie. De 
respondenten in het enquête-onderzoek zouden huisartsen geweest kunnen zijn met 
een bijzondere interesse in de dermatologie, die daarom vaker een biopt afnemen. 
Met betrekking tot de klinisch diagnostische vaardigheden van huidkanker vonden we 
dat in 39.8% van de verwijsbrieven een juiste diagnose vermeld stond. In een evaluatie 
van 1898 pathologieverslagen (paragraaf 3.3) vonden we een correcte diagnose in 
21.6% van de BCCs, 0% van de PCCs en 8.7% van de melanomen. Hoewel behandeling 
van PCCs en melanomen in de eerste lijn niet de voorkeur heeft, moeten huisartsen wel 
in staat zijn deze maligniteiten te herkennen om ze tijdig door te kunnen verwijzen naar 
de dermatoloog. 
 In de analyse van de verwijsbrieven bleek dat van 38 histologisch bevestigde PCCs er 
slechts 6 onder de diagnose PCC verwezen waren. In 15.4% van de verwijsbrieven werd 
een adequate beschrijving van de laesie gegeven door middel van dermatologische 
Zoals in hoofdstuk 2 werd beschreven zijn de patiënten die in deze studie zijn 
geïncludeerd slechts een selectie van de totale huidkanker populatie. Daarom zou het, 
om een juiste inschatting te maken van de totale omvang van deze populatie, goed zijn 
om een complete registratie op te zetten waarin zowel premaligniteiten als maligniteiten 
van de huid worden geregistreerd. In Denemarken zijn pogingen gedaan om een soort- 
gelijke database voor NMSC op te zetten3. Wat zij ontdekten was dat deze database zeker 
potentie had als bron voor epidemiologische studies naar NMSC. Er waren  echter 
verbeteringen nodig om tot complete registratie van alle tumoren te komen.  
 Een volledige registratie van alle (pre)maligniteiten van de huid kan ook van toegevoegde 
waarde zijn voor het berekenen van de vergoeding voor deze populatie. Momenteel staat 
voor de behandeling en FU van patiënten met huidkanker een maximale vergoeding. 
Deze vergoeding is toereikend voor de ‘normale’ huidkanker patiënt. Echter, de vraag is of 
deze vergoeding ook voldoende is voor die 10.8% van de academische populatie (zoals 
beschreven in hoofdstuk 2) met >10 maligniteiten van de huid. Zeker wanneer deze 
patiënten zich met meerdere tumoren tegelijk presenteren, zoals in de praktijk vaker het 
geval blijkt te zijn. 
2a.   De rol en vaardigheden van huisartsen in de huidige huidkankerzorg in  
kaart brengen. 
In het Nederlandse zorgsysteem hebben huisartsen een poortwachtersfunctie. Vanuit 
deze positie zijn zij vaak de eerste die de huidkankerpatiënt ziet. Daarom is de diagnostiek 
van huidkanker door de huisarts, gevolgd door een adequate behandeling en/of verwijzing, 
van groot belang. Tevens kunnen huisartsen een significante rol spelen in de primaire 
en secundaire preventie van huidkanker door het geven van zonprotectie advies en het 
verrichten van huidinspectie bij patiënten met een door de zon beschadigde huid 
(actinische schade). Tot op heden zijn slechts een klein aantal studies verricht naar de rol 
en kennis van huisartsen in de Nederlandse huidkankerzorg. In hoofdstuk 3 van dit 
proefschrift zijn drie paragrafen gewijd aan dit onderwerp. 
In paragraaf 3.1 worden de resultaten uit een enquête beschreven waaruit blijkt dat 
huisartsen behoefte hebben aan nascholing op het gebied van huidkanker, voornamelijk 
wanneer het gaat om het diagnosticeren van Morbus Bowen (MB), plaveiselcelcarcinoom 
(PCC) en melanoom. We vonden ook dat slechts 3% van de huisartsen vindt dat de 
behandeling van PCC thuishoort in de eerste lijn. Daarnaast is het zo dat in het geval van 
een melanoom de Nederlandse richtlijn adviseert om de patiënt naar een dermatoloog 
te verwijzen4. Met betrekking tot AK vonden we dat 75% van de huisartsen vindt dat 
deze in de eerste lijn behandeld kunnen worden, in het geval van een BCC vindt 20% dit. 
Een additionele 33.2% zou enkel laagrisico BCCs behandelen.  
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 Een bemoedigende bevinding is dat de risicofactoren voor het ontwikkelen van 
huidkanker bekend zijn bij 93% van de huisartsen. Echter, 70.5% heeft behoefte aan 
scholing op het gebied van risicofactoren. Als het effect van nascholing over risicofactoren 
leidt tot een toename van  zonprotectie-advies in de eerste lijn, dan is dit zeker de moeite 
waard. Het blijkt namelijk dat zonprotectie-advies, wanneer persoonlijk gegeven door 
een huisarts, leidt tot een verbetering in het zonbeschermingsgedrag over lange tijd14.  
Een beperking van de studies naar de vaardigheden van huisartsen in de huidkankerzorg 
is dat deze gebaseerd zijn op die patiënten waarbij actie ondernomen is. De data 
beschreven in paragraaf 3.2 en 3.3 zijn van patiënten die dan wel verwezen zijn of 
waarbij materiaal voor pathologisch onderzoek is weggehaald. De data die ontbreken 
zijn die van patiënten waarbij de huidkanker niet als dusdanig is herkend en geen actie is 
ondernomen of het afgenomen materiaal niet naar de patholoog is gestuurd. Om ook 
inzicht in deze populatie te krijgen zou de huisarts gedurende zijn dagelijkse praktijk 
gevolgd moeten worden. Een dergelijk onderzoek is helaas moeilijk in de praktijk uit te 
voeren. 
2b.  Een beeld vormen van de toekomstige rol van de huisarts in de huidkankerzorg
Wanneer het gaat om de toekomstige rol van de huisarts in de huidkankerzorg, zijn de 
data omtrent de huidige rol zoals beschreven bij 2a. uiteraard van belang. Daarnaast zal 
hieronder aanvullende data, zoals beschreven in hoofdstuk 3, worden samengevat. 
 In een enquête, waarin huisartsen gevraagd werd naar hun rol in de huidkankerzorg, 
gaf 93.7% aan dat zij huidkanker zien als een gezondheidsprobleem waarin zij een rol 
dienen te spelen, 86.0% wil hierin zelf een grotere rol spelen. Dit zijn bemoedigende resultaten, 
aangezien de mogelijkheid tot gedeeltelijke verplaatsing van de huidkankerzorg naar de 
eerste lijn valt of staat bij de bereidheid van huisartsen om hierin deel te nemen. 
 Zoals eerder beschreven geeft 89.2% van de huisartsen aan AKs zelf te behandelen. 
Dit aantal neemt niet toe na nascholing, waarschijnlijk omdat het aantal huisartsen dat AK 
reeds behandeld al hoog is. Echter, wanneer naar de behandelmethode voor AK wordt 
gevraagd, blijkt dat de meeste huisartsen voornamelijk gebruik maken van cryotherapie 
en dat topicale (veld) behandeling amper gebruikt wordt.
 Het aantal huisartsen dat BCC zou behandelen, na hierin geschoold te zijn, is 51.9%, 
voor MB is dit 42.2%. Het percentage huisartsen dat PCCs of melanomen zou behandelen 
blijft laag na aanvullende scholing, respectievelijk 19.8% en 2.2%.
 Alvorens de behandelvaardigheden van huisartsen uit te breiden zullen ook de 
diagnostische vaardigheden aangescherpt moeten worden, zodat huisartsen zich 
bewust zijn van de aard van de tumor die zij behandelen. De data, zoals beschreven in 
hoofdstuk 3, laat zien dat huisartsen moeite hebben met het diagnosticeren van 
huidkanker. Uit een analyse van verwijsbrieven bleek dat de helft van de patiënten 
verwezen was met wat uiteindelijk benigne laesies bleken te zijn en dat slechts de helft 
 efflorescenties. Dit laatste is een belangrijke bevinding aangezien een goede laesiebe-
schrijving de dermatoloog kan helpen in de triage, zeker wanneer een correcte verwijsdi-
agnose ontbreekt. 
 Een beperkende factor in de analyse van de verwijsbrieven is dat deze geen 
compleet beeld geeft van de totale huidkankerzorg zoals deze in de eerste lijn geleverd 
wordt. Om die reden zijn tevens pathologieverslagen, van materiaal dat door huisartsen 
is ingestuurd, geanalyseerd (paragraaf 3.3). De door huisartsen meest gebruikte 
methoden voor het verzamelen van materiaal van huidtumoren waren: primaire excisie 
(zonder voorafgaand biopt) (58.4%), shave/curettage (22.3%) en diagnostische biopten 
(17.9%). Na pathologisch onderzoek bleek bijna 90% van al het tumormateriaal benigne. 
Hieruit kan worden afgeleid dat huisartsen hoge aantallen benigne laesies excideren. 
Ook zagen we dat huisartsen maar zelden maligniteiten excideren: in totaal 159 NMSC 
voor alle huisartsen samen (< 1 per huisarts) en 1 melanoom per 7 huisartsen. Dit kan ook 
een verklaring zijn voor het hoge aantal niet-radicaal geëxcideerde laesies; 65.4% in het 
hoofd-hals gebied, 29.5% op de romp en 10.7% op de extremiteiten. Dat huisartsen 
moeite hebben met de radicale excisie van tumoren van de huid wordt door verschillende 
buitenlandse studies bevestigd. In een Britse studie bleek dat in 68% (15/22) van de 
excisie biopten die huisartsen uitvoerden in melanomen, BCCs en dysplatische naevi, de 
randen niet vrij waren van tumorweefsel10. Helaas was van deze tumoren de locatie niet 
vermeld. In een Schotse studie werd gevonden dat huisartsen kleinere laesies excideren 
dan dermatologen, minder gebruik maken van diagnostische methoden en dat 23.1% 
van de huidkanker niet radicaal werd geëxcideerd, met het hoogste percentage binnen 
de melanomen (34.6%)11.
 Met betrekking tot de screenings- en FU vaardigheden van huisartsen, bleek uit onze 
enquête dat huisartsen in geval van BCC een totale huidinspectie doen bij 34% van de 
patiënten en in geval van PCC bij 19%. Van alle ondervraagde huisartsen geeft 27% aan 
bekend te zijn met de FU richtlijn voor het BCC. Het is bekend dat patiënten multipele 
(pre)maligniteiten van de huid ontwikkelen (hoofdstuk 2) en dat huidkanker ook op de 
minder frequent aan ultraviolet (UV) licht blootgestelde delen van de huid voor kan 
komen12. Daarom kan het niet uitvoeren van totale huidinspecties bij huidkankerpatiënten 
als inaccuraat beschouwd worden, zeker bij die patiënten die niet naar de dermatoloog 
verwezen worden voor FU. Uit onderzoek is gebleken dat het niet uitvoeren van totale 
huidinspectie er toe kan leiden dat 1 op de 3 melanomen wordt gemist13. 
 Het op grote schaal ontbreken van de uitvoering van totale huidinspectie wordt ook 
in paragraaf 3.2 besproken. In deze paragraaf wordt beschreven dat bij patiënten, na 
verwijzing door de huisarts, nog 234 extra premaligne en maligne laesies werden 
gevonden. In de verwijsbrieven van deze patiënten stonden voornamelijk solitaire laesies 
in het gezicht beschreven, tumoren die zichtbaar zijn zonder dat de patiënt zich dient te 
ontkleden. 
128 129
CHAPTER 7 NEDERLANDSE SAMENVATTING EN DISCUSSIE
7
 Zoals uiteengezet in hoofdstuk 2, zijn er in de ziekenhuispopulatie veel patiënten 
die meer dan één (pre)maligniteit van de huid ontwikkelen. Het is de vraag of al deze 
patiënten in het ziekenhuis vervolgd moeten worden. In hun toekomstige rol in de 
huidkankerzorg zouden huisartsen de FU van laag risico huidkankerpatiënten op zich 
kunnen nemen. Echter in dit geval moeten er richtlijnen voor de eerste lijn beschikbaar 
komen en dienen huisartsen totale huidinspectie te verrichten. 
3.  Inzicht krijgen in de toegevoegde waarde van het biopt in de diagnostiek van BCC 
Bij het diagnosticeren van een BCC wordt aangeraden een biopt te nemen. Uit 
verschillende studies waarin de overeenkomst tussen het BCC subtype na biopt 
vergeleken is met de diagnose na de aanvullende excisie, bleek een overeenkomst van 
60.9%-72.3%23-25. Een verklaring voor dit verschil is ‘sampling error’, waarbij het meest 
agressieve subtype wordt gemist. 
 In hoofdstuk 4 wordt een overzicht gegeven van de radicaliteit en efficiëntie (in tijd) 
van BCCs geëxcideerd door de dermatoloog met en zonder voorafgaand biopt. Een totaal van 
357 excisies na biopsie en 844 primaire excisies (zonder voorafgaand biopt) werden 
geëvalueerd. In 84.2% van alle laesies, geëxcideerd onder verdenking van een BCC, werd 
deze diagnose histologisch bevestigd. Met betrekking tot de radicaliteit van de excisies 
werd geen significant (P = 0.179) verschil gevonden tussen excisies na biopt en primaire 
excisies. Analyse van de verschillende BCC subtypen liet zien dat binnen de nodulaire 
BCCs (nBCC) significant (P = 0.047) meer excisies na biopt radicaal geëxcideerd waren. 
 Door de retrospectieve opzet van het onderzoek was het niet mogelijk een verklaring 
voor dit verschil te vinden omdat data over de gebruikte excisiemarges, tumorlokatie 
en -grootte ontbraken. Daarnaast was het niet mogelijk om inzicht te krijgen in de 
overwegingen die de dermatoloog ertoe hebben bewogen voor een bepaalde procedure 
te kiezen.  
 In de groep van de niet-radicaal geëxcideerde infiltratieve BCCs (iBCC) werd een 
significant hoger aantal afwijkende BCC subtypes in de biopten voorafgaand aan excisie 
gevonden. Dit zou er op kunnen wijzen dat het nemen van een biopt (met een ander 
BCC subtype als uitkomst) leidde tot kleinere excisie marges en daardoor een niet-radicale 
excisie. 
 Met betrekking tot de efficiëntie van de primaire excisies werd gevonden dat, bij een 
gemiddelde excisietijd van 13 minuten, een primaire excisie efficiënter is wanneer het 
nemen van een biopt langer duurt dan 1.94 minuten. Aangezien de excisietijd kan 
variëren per tumor, werd een ‘two-way’ sensitiviteitsanalyse uitgevoerd om een overzicht 
te maken van de meest efficiënte methode afhankelijk van de excisie en biopsietijd 
(hoofdstuk 4). In deze analyse werd alleen de tijd geïncludeerd die de arts kwijt was aan 
het uitvoeren van een exisie of biopt. In de dagelijkse praktijk zijn er meer factoren die 
een rol spelen, zoals de tijd van de verpleegkundige ondersteuning, additionele tijd voor 
telefonische consulten na een biopt en de kosten van het biopt. In sommige specifieke 
van de patiënten die onder verdenking van een BCC werd verwezen ook daadwerkelijk 
een BCC had. Daarnaast zijn van de 125 als verruca seborrhoica gediagnosticeerde laesies, 
42 laesies verwezen onder verdenking van een atypische naevus. Deze bevindingen 
worden ondersteund door voorgaande studies waaruit blijkt dat huisartsen moeite 
hebben met het diagnosticeren van tumoren van de huid15-18.
 Daarnaast blijkt dat huisartsen slechts op kleine schaal gebruik maken van diagnostische 
hulpmiddelen19. Terwijl deze middelen juist van betekenis kunnen zijn in het optimaliseren 
van de huidkankerzorg. Het nemen van een biopt in geval van NMSC kan van educatieve 
waarde zijn omdat de huisarts op deze manier directe feedback krijgt op de klinische 
diagnose. Daarnaast kan dit het aantal onnodige excisies en verwijzingen van benigne 
laesies omlaag brengen. Een ander diagnostisch hulpmiddel is de dermatoscoop die, mits 
in getrainde handen, onder andere kan helpen in de differentiatie tussen verschillende 
gepigmenteerde laesies20-22. Trainen van huisartsen in het dermatoscopisch herkennen 
van de meest voorkomende laesies (naevi, verrucae seborrhoicae, angiomen) kan 
onnodige verwijzingen en excisies voorkomen. 
 Met betrekking tot de behandeling van huidtumoren in de eerste lijn zijn er een 
aantal zaken die aandacht behoeven in nascholingen. Zoals eerder besproken excideren 
huisartsen voornamelijk benigne laesies met primaire excisie. Het aantal van deze excisies 
kan verlaagd worden door gebruik van curretage of shave excisies. Deze behandel-
methodes zijn minder invasief en in geval van twijfel over de diagnose leveren ze 
voldoende materiaal op voor pathologisch onderzoek. Het aantal excisies zou nog verder 
gereduceerd kunnen worden door toenemend gebruik te maken van topicale middelen 
in de behandeling van oppervlakkige BCCs (sBCC). Uit onderzoek is gebleken dat gebruik 
van deze middelen kosteneffectief is6,7. Het gebruik van topicale middelen voor patiënten 
met multipele AK in de eerste lijn kan bijdragen aan de reductie van verwijzingen uit 
deze populatie en kan bij dragen aan de preventie van PCCs. Zoals beschreven in 
hoofdstuk 5, zijn zowel IMI als 5-FU effectieve middelen die de huisarts kan gebruiken in 
de veldbehandeling van AK. Daarnaast is sinds kort ingenolmebutaat op de markt 
verschenen als nieuwe topicale methode voor AK. 
Bij de chirurgische behandeling van huidkanker dienen huisartsen zich bewust te zijn van 
hun eigen chirurgische vaardigheden. Zoals in paragraaf 3.3 is beschreven zijn excisies 
uitgevoerd door huisartsen vaak niet-radicaal, met name in het gezicht. De data uit deze 
paragraaf is een gemiddelde van data van 161 huisartsen, natuurlijk kunnen er op 
individueel niveau verschillen zijn. Echter, gezien het dusdanig grote aantal niet radicaal 
geëxcideerde tumoren in het gezicht, willen wij huisartsen adviseren deze tumoren door 
te verwijzen voor behandeling. Verder zal er voor huisartsen die zelf willen excideren 
onderwijs gericht op operatietechnieken en richtlijn gebruik (oa. excisie marges), 
georganiseerd moeten worden. 
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ziekenhuis wordt uitgevoerd en is de behandeling na één bezoek voltooid. Dit kan een 
verklaring zijn voor het hoge aantal AKs en het grotere oppervlak te behandelen huid in 
deze groep. 
 Het gemiddelde aantal AK was 32 in de MAL-PDT groep, 20 in de IMI groep en 23 in 
de 5-FU groep. Deze aantallen laten zien dat, zoals ook in hoofdstuk 2 beschreven, 
patiënten in de dagelijkse praktijk veel ernstiger zijn aangedaan dan in klinische trials. 
 Aangezien het doel van deze studie, het verzamelen van data uit de dagelijkse 
praktijk was, is gekozen voor een observationele studie-opzet. Deze opzet heeft geleid 
tot significante verschillen op baseline tussen de behandelgroepen. Daarom zijn de data 
met betrekking tot de effectiviteit en kosten van de behandeling per groep beschreven 
en niet vergeleken tussen de groepen. 
 Het gemiddeld percentage laesie-reductie na 3 maanden was 79.4% voor MAL-PDT, 
80.0% voor IMI en 89.5% voor 5-FU. Na 12 maanden was dit respectievelijk  81.1%, 81.7% 
en 88.5%. Hierbij moet in acht worden genomen dat de meeste patiënten aanvullende 
behandeling hebben gehad wanneer dit nodig was en dat niet alle patiënten een 
tweede cyclus van de initiële behandeling kregen bij resterende AK. In de dagelijkse 
praktijk blijkt dat wanneer slechts een klein aantal AK resteren, de voorkeur uit gaat naar 
cryotherapie als aanvullende behandeling. Dit wijkt af van de PDT en IMI richtlijnen 
waarin wordt geadviseerd een tweede cyclus van deze behandeling te geven bij 
onvoldoende effect na de eerste cyclus. Uiteindelijk is de keuze voor cryotherapie, zoals 
gemaakt in de dagelijkse praktijk, goedkoper en sneller dan een extra cyclus PDT of IMI. 
 Met betrekking tot de behandel- en FU kosten over 1 jaar vonden we gemiddelde 
kosten van €1949.90 voor MAL-PDT, €877.17 voor IMI en €738.41 voor 5-FU. In een eerder 
onderzoek uitgevoerd in België, met een FU van 6 maanden, werden totale kosten van 
€381 voor MAL-PDT gevonden31. Echter in deze studie is een kortere FU gebruikt, zijn 
minder additionele kosten geïncludeerd (zoals dagopname) en hadden patiënten een 
gemiddelde van 7.1 AK.
 Gebaseerd op de patiëntkarakteristieken, effectiviteit en kosten kunnen we concluderen 
dat MAL-PDT gereserveerd dient te worden voor een specifieke patiëntenpopulatie, 
te weten patiënten met hardnekkige en uitgebreide AK die niet in staat zijn zelfstandig 
een thuisbehandeling toe te passen. 
Conclusie en toekomst perspectief 
Huidkankerpatiënten, onderzocht in de dagelijkse praktijk, blijken ernstiger aangedaan te 
zijn dan patiënten uit klinische trials. Hieruit kan geconcludeerd worden dat resultaten 
van (gerandomiseerde) trials niet altijd toepasbaar zijn op de dagelijkse praktijk. Observationele 
studies, die een duidelijker beeld geven van de alledaagse praktijk, kunnen bijdragen aan 
het invullen van het hiaat aan kennis dat nodig is voor het leveren van zorg op maat. 
gevallen is het uitvoeren van een biopsie belangrijk in het maken van de behandelkeuze, 
bv. bij topicale behandeling in geval van sBCC of wanneer Mohs chirurgie of bestraling 
geïndiceerd is bij een hoog risico BCC. Ook omdat de diagnostische kwaliteit van een 
biopt nog steeds groter is dan de klinische blik van de dermatoloog in het subtyperen 
van een BCC26. 
 Op basis van onze data is het moeilijk om te bepalen of en in welke gevallen het 
diagnostisch biopt in de toekomst achterwege gelaten kan worden. Om meer inzicht te 
krijgen in de effectiviteit en efficiëntie van het biopt zal prospectief onderzoek uitgevoerd 
moeten worden. 
 De discussie over de noodzaak van het biopt is voornamelijk relevant voor de 
 dermatologische praktijk. Hoewel dit niet direct in dit proefschrift is onderzocht, lijkt het 
gerechtvaardigd om in geval van verdenking op een BCC in de eerste lijn, zoals beschreven 
in hoofdstuk 3, het nemen van een biopt aan te bevelen, aangezien de diagnostische 
accuratesse van huisartsen een stuk lager ligt dan die van de dermatoloog. 
4.   Het in kaart brengen van patiëntkarakteristieken, effectiviteit en kosten bij 
behandeling van veld AK.  
In het verleden zijn reeds studies verricht naar de kosten en effectiviteit van veldbehan-
deling bij AK. Echter, de meeste van deze studies zijn gebaseerd op gerandomiseerde 
trials met patiënten met slechts enkele AKs, waardoor deze data niet geheel van 
toepassing zijn op de dagelijkse klinische praktijk27-30. 
 In hoofdstuk 5 wordt een overzicht gegeven van klinische gegevens uit de 
dagelijkse praktijk van 320 patiënten die veldbehandeling kregen voor AKs in een 
observationele multicenter-studie. Alle geïncludeerde patiënten hadden AKs op het 
gezicht en/of scalp die geschikt waren voor behandeling met methylaminolevulinaat 
fotodynamische therapie (MAL-PDT), IMI of 5-FU. 
 Er bleken significante verschillen te zijn tussen de behandelgroepen in de op 
baseline gedocumenteerde patiëntkarakteristieken. Patiënten in de MAL-PDT groep 
hadden het hoogste aantal voorafgaande behandelingen, hoogste percentage van 
zowel gezicht als scalp aangedane huid en een significant hoger aantal AKs. Patiënten die 
met IMI werden behandeld waren vaker vrouwen, met een lagere leeftijd en het laagste 
aantal AKs. Dit laatste is niet verassend, aangezien IMI slechts voor een klein oppervlak 
gebruikt kan worden. Patiënten in de 5-FU groep waren vaker mannen, met de hoogste 
leeftijd en het hoogste aantal SCC in de voorgeschiedenis. De behandelkeuze werd door 
de arts in samenspraak met de patiënt gemaakt op basis van de voor- en nadelen van 
elke behandeling. Dit kan een aantal van de op baseline bestaande verschillen verklaren. 
Zo is PDT geregistreerd als behandeling voor therapieresistente AK, vandaar dat deze 
behandeling vaker gekozen zal worden als voorafgaande (andere) behandelingen niet 
effectief zijn gebleken. Dit kan een verklaring zijn voor het hoge aantal voorafgaande 
behandelingen in de MAL-PDT groep. Daarnaast is PDT een behandeling die in het 
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